--- a
+++ b/clusters/3009knumclusters/clust_59.txt
@@ -0,0 +1,2354 @@
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomization
+PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) =< 3 x ULN for subjects with Gilbert’s disease or with atazanavir- or indinavir-induced unconjugated hyperbilirubinemia without aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation and must have a total bilirubin less than 3.0 mg/dL, within 2 weeks prior to enrollment
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN within 30 days of day 1 of study
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 times upper limit of normal (ULN); obtained within 14 days prior to study entry
+Alanine aminotransferase ? 5 × upper limit of normal (ULN) for age
+Aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULN
+Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x institutional upper limit of normal (IULN) within 28 days prior to registration
+Within 6 weeks prior to randomization: Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab\r\n* Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be =< 1.5 x ULN
+Within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 3 x IULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (IULN) (or =< 5 x IULN if liver metastases are present)
+Serum alanine aminotransferase (ALT) < 2.5 x ULN
+Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to sub-study registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x institutional upper limit of normal (IULN) within 14 days prior to step 2 randomization
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
+Re-registration: AST/ALT =< 3 x ULN
+Transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x institutional upper limit normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x IULN within 28 days prior to registration
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN); if liver metastases, =< 5 x upper limit of normal (ULN)
+Alanine (ALT) or aspartate (AST) aminotransferase > 1.5 x ULN
+Within 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)
+Within less than or equal to 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Obtained =< 48 hours prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+Within 14 days of registration: Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (=< 5 x IULN secondary to lymphoma) within 28 days prior to registration
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 1.5 x the upper limit of normal
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Obtained within 28 days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 4 weeks of randomization
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limits of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x institutional ULN, within 21 days prior to registration
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registration
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 1 registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 3 registration
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
+Patients must have aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times institutional upper limit of normal with or without liver metastasis, within 21 days prior to study entry
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limits of normal (ULN)\r\n* Unless due to hepatic metastases in which case levels =< 5 x ULN are allowed
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Obtained within 14 days prior to treatment start: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST must still be =< 2.5 x ULN; patients with liver metastases and AST/ALT above this limit will not be enrolled
+Aspartate aminotransferase (AST) =< 3.0 X ULN, within 14 days of registration
+Alanine aminotransferase (ALT) =< 3.0 X ULN, within 14 days of registration
+Aspartate Aminotransferase (AST) ? 3.0x the upper limit of normal (ULN)
+AST/ALT ?2.5 × ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 3.0 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Hepatic: bilirubin <1.5 X Upper Limit of Normal (ULN); alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3X the institutional ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times the institutional ULN (unless elevated secondary to lymphomatous involvement of the liver, in which case the AST/ALT must be =< 5 times the institutional ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
+Serum transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) less than three times the upper limits of normal (ULN)
+Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN (may not have abnormalities in both bilirubin and transaminases)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal for age
+ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Adequate liver function with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
+Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3×ULN; however, ALT, AST, and TBILI each ? 5×ULN is acceptable if the elevation is considered due to PTLD involvement of the liver.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for patients with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 × upper limit of normal (ULN); if liver metastases, then < 5 × ULN
+Serum AST and ALT ? 3 X ULN
+Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis) (=< 28 days prior to registration)
+Aspartate aminotransferase (AST) =< 2.5 x ULN obtained within 14 days prior to registration
+Alanine aminotransferase (ALT) =< 2.5 x ULN obtained within 14 days prior to registration
+Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (or =< 5.0 x ULN if liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 3.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN) must be met within 28 days of C1D1
+Patients with aspartate aminotransferase (AST) =< 3 x upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN\r\n* Note that physician attestation of patient having no known history of liver disease can take the place of bilirubin and AST/ALT labs
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN.
+In case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 1.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN; if liver metastases are present, then ? 5 x ULN is allowed.
+Liver function tests above the following limits at Screening: total bilirubin >1.5 x upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for subjects with liver involvement, AST and/or ALT >5 x ULN;
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at most 3 x ULN.
+Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
+INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X the upper normal limit of institution's normal range
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and/or ALT ? 2.5 × ULN
+Subject has a total bilirubin ? 1.5 x upper limit of normal (ULN), albumin ? 2.5 g/d, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN)
+Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 2.5 x ULN in the absence of liver metastases and =< 5 x ULN in case of liver metastases
+Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal if no documented liver disease or < 5 x upper limit of normal if documented liver disease
+alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal as per local laboratory. Additional inclusion required for donor arm participants to proceed with transplant
+Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) < 2.5 × ULN; serum bilirubin < 1.5 × ULN
+Adequate liver function (total bilirubin ? 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN
+Aspartate aminotransferase (AST) ? 1.5 x upper limits of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; for patients with hepatic metastases, ALT and AST =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x ULN; if liver metastases, ALT/AST =< 5.0 x ULN
+Within 30 days prior to enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN);
+Aspartate aminotransferase and alanine aminotransferase ?3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (ULN) in the absence of malignancy within the liver within 14 days of starting cycle 1 day 1 treatment
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ?2.5 upper limit of normal (ULN).
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × the upper limit of normal (ULN) (=< 5 × ULN if considered due to primary or metastatic liver involvement)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) < 5 times ULN
+Alanine aminotransferase (ALT) < 5 times ULN
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
+Serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
+Alanine aminotransferase or aspartate aminotransferase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasis
+Serum ALT and AST levels ?2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST [SGOT]) ?2.5 × the ULN;
+Alanine aminotransferase (ALT [SGPT]) ?2.5 × the ULN;
+AST and ALT are each ?5 × the ULN;
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the ULN; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal, within 14 days before the first dose of cabozantinib
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) (SGOT) less than or equal to 3 x UNL
+Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULN
+Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Hepatic: Bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) ? 3.0 times ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal range
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST), should be less than or equal to 1.5 x ULN (CTCAE v4.0, grade 1); for patients with liver metastases, ALT/AST should be less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
+Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN
+TREATMNET: Aspartate aminotransferase (AST) =< 3 x upper limit of normal
+If requires pheresis to collect blood, aspartate aminotransferase (AST) < 1.5 upper limit of normal
+Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registration
+Aspartate aminotransferase (AST) =< 5 x normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN within 7 days before the first dose of cabozantinib
+Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN; AST and ALT ? 5 × ULN for patients with liver metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST must be =< 5 x ULN.
+AST and ALT ? 5 x ULN
+Within 10 (except as noted) days of planned treatment initiation: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN OR =< 5 x ULN for patients with known liver metastases
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ? 3 upper limit of normal (ULN). In cases with liver involvement ALT/ AST ? 5× ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
+PHASE II INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ?5 times upper limit of normal (ULN)
+AST and ALT must be ? 1.5 x ULN for the lab.
+Obtained within 14 days prior to C1D1: Aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 14 days prior to C1D1: Alanine aminotransferase (ALT) =< 3 x ULN
+In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) should be below 3.0 × ULN. If the participant has liver metastases, ALT and AST should be below 5.0 × ULN.
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is attributed to leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 × ULN
+Obtained =< 21 days prior to registration: aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
+Obtained =< 21 days prior to registration: alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 10 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3× the ULN (in the case of liver metastases ?5× the ULN). Participants with bone metastases with ALP values greater than 3 times can be included.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × institutional ULN.
+Aspartate and alanine aminotransferase (AST and ALT) =< 2.5 x ULN; =< 5.0 x ULN if there is liver involvement secondary to tumor
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
+Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN
+Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN
+Obtained =< 2 weeks prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN (=< 5 x ULN if liver metastasis)
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 5 x ULN
+Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 5 x ULN
+Aspartate aminotransferase (AST) ? 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN or < 5 x the ULN if liver metastasis performed within 30 days prior to the date of registration
+Alanine aminotransferase (ALT) =< 3 x ULN, aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) > 5 times ULN
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if a patient has liver metastases, ALT and AST < 5 x ULN
+Aspartate aminotransferase (AST) < 2 x institutional upper limit of normal (ULN) within 14 days of enrollment to trial
+Alanine aminotransferase (ALT) < 2 x institutional ULN within 14 days of enrollment to trial
+alanine aminotransferase /aspartate aminotransferase (ALT/AST) ?2.5 x ULN without, and ? 5 x ULN with hepatic metastases
+Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3.0 x ULN; for patients with hepatic metastases, ALT and AST =< 5.0 x ULN are acceptable\r\n* Note: if a patient experiences elevated ALT > 5 x ULN and elevated total bilirubin > 2 x ULN, clinical and laboratory monitoring should be initiated by the investigator; for patients entering the study with ALT > 3 x ULN, monitoring should be triggered at ALT > 2 x baseline
+Alanine aminotransferase (ALT) =< 3.0 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal
+aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Clinically-significant inadequate hematological, hepatic and renal function, defined as: Neutrophil count < 1.5 x 10 9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate transaminase (AST) and/or alanine aminotransferase (ALT) > 2.5 x ULN or > 5 x ULN if patient has documented liver metastases; and serum creatinine > 1.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 14 days prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases within 8 weeks of pre-registration
+Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).
+Serum AST and/or ALT < 3 x institutional ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
+INCLUSION - INFUSION: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (ALT) and alanine aminotransferase (AST) =< 3 x ULN
+Adequate hepatic function, with total bilirubin ?1.5 x upper limit of normal (ULN) (except for Gilbert Syndrome: total bilirubin < 3.0 x ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3.0 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Hepatic: Total bilirubin < 3.0 x the upper limit of normal (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5.0 x ULN for age.
+TREATMENT INCLUSION: Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
+Obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
+Obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3X upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 5 x upper limit normal (ULN)
+Aspartate aminotransferase (AST) =< upper limit of institutional normal
+Aspartate aminotransferase (AST) < 2 x upper normal limit
+Alanine aminotransferase (ALT) < 2 x upper normal limit
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
+ALT and AST ? 3 × ULN
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer or stent placement)
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN or =< 5 x ULN if liver mets are present
+Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ? 10 x upper limit of normal for age
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the institutional upper limit of normal (IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal (IULN) except for Gilbert’s disease or when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia), in which case ALT and AST may be elevated up to =< 5 x IULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN OR ?5 × institutional ULN for participants with liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at =< 2.5 x ULN (in case of liver metastasis AST/ALT at =< 5.0 x ULN)
+ALT and AST ? 1.5 ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ?5 times ULN).
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?3.0 × the upper limit of normal(ULN), even in the presence of liver metastases.
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? 2.5 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/alkaline phosphatase: =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 times the upper limit of institutional normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Patients without underlying liver disease\r\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X institutional upper limit of normal
+Alanine aminotransferase (ALT) =< 1.5 x institutional ULN
+Aspartate aminotransferase (AST) =< 1.5 x institutional ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 x the upper limit of normal
+Aspartate aminotransferase (AST) ? 3 X upper limit of normal
+Alanine aminotransferase & Asparate aminotransferase ? 2.5 x upper limit or normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+PHASE I: Transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+ALT (alanine aminotransferase; SGPT), AST (aspartate aminotransferase; SGPT), alkaline phosphatase (ALP) >2.5 upper limit of normal (ULN), unless attributed to GVHD.
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x ULN for patients without tumor involvement of the liver or >5 x ULN for patients with tumor involvement of the liver.
+OBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Aspartate aminotransferase (AST) =< 2 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limit of institutional normal
+Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
+Alanine aminotransferase and aspartate aminotransferase ? 3 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limit of normal
+Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 3 x ULN; (up to 5 x ULN if liver metastases present)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN)
+ELIGIBILITY CRITERIA AT TIME OF TREATMENT: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
+Clinically significant hepatic dysfunction (alanine or aspartate aminotransferase > 7 times the upper limit of normal)
+Aspartate aminotransferase (AST) ? 3x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 times upper limit of normal
+Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for patients with liver metastases
+ALT/AST ? 2 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 times the ULN; if liver metastases are present, then ? 5 times the ULN is allowed.
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+AST (aspartate aminotransferase) and ALT (alanine aminotransferase) < 3 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) up to 2.5 x upper limits of normal (ULN).\r\n* Patients known to have Gilbert’s disease may be eligible with AST and ALT up to 5 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the institutional upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit
+Aspartate aminotransferase (AST) =< 3 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x the ULN
+Aspartate aminotransferase (AST) ? 3 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN within four weeks of enrollment
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x the upper limit of normal (ULN), if no liver involvement or ?5 x ULN with liver involvement
+INCLUSION - TREATMENT: Aspartate aminotransferase (AST) ? 5x
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULN
+Aspartate aminotransferase (AST), alanine aminotransferase, (ALT) =< 3.0 x institutional upper limit of normal (ULN)
+Alanine aminotransferase (ALT) > 2.5 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X ULN (or < 5 x ULN with liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3.0 x institutional ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 x the ULN for the reference lab (=< 5 x the ULN if there is evidence of hepatic involvement by malignant disease)
+Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) =< 2 x ULN (upper limit of normal)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
+Aspartate and alanine aminotransferase (AST or ALT) =< 2 times the upper limit of the reference range
+Aspartate aminotransferase (AST) and alanine-aminotransferase (ALT) levels =< 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than five times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of reference range
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limits of normal
+Aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastases
+Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN, (=< 5.0 x ULN with documented liver metastases) within 14 days prior to first dose of protocol-indicated treatment.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception: patients with liver involvement: AST and/or ALT =< 5 x ULN.
+TREATMENT WITH SJCAR19: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 times the upper limit of normal for age
+Within 14 days of the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x ULN
+Within 14 days of the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5.0 x upper limit of normal (ULN).
+Hepatic: < 5 x upper limit of normal (ULN) alanine aminotransferase (ALT).
+Aspartate aminotransferase (AST) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.
+Alanine aminotransferase (ALT) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.
+Aspartate aminotransferase (AST) level =< 2.5 × ULN.
+Alanine aminotransferase (ALT) level =< 2.5 × ULN.
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 5 times upper limit of normal (ULN)
+Alanine aminotransferase (ALT) < 3 x ULN, unless due to the underlying leukemia approved by the PI
+Aspartate aminotransferase (AST) < 3 x ULN unless due to the underlying leukemia approved by the PI
+Alanine aminotransferase (ALT) ? 3 x ULN for age, unless elevation is due to leukemic infiltration
+Serum alanine aminotransferase (ALT) or aspirate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3x the ULN (?5x the ULN for subjects with liver metastases)
+Obtained ? 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x institutional ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN, unless liver metastases are present, then values must be ? 5 x ULN)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN)
+Hepatic impairment as defined by alanine transaminase (ALT) or aspartate aminotransferase (AST) levels greater than 2 times the upper limit of normal
+ALT and AST ?2.5 x ULN
+Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN unless deemed to be related to underlying leukemia.
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) ? 3.0 x ULN (unless considered due to leukemic organ involvement)
+Alanine aminotransferase (ALT) ? 3.0 x ULN (unless considered due to leukemic organ involvement)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULN
+Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2x upper limit of normal (ULN) compatible for surgery
+Alanine aminotransferase (ALT) greater than 2.0 times the ULN in the absence of known hepatic metastases
+Aspartate aminotransferase (AST) greater than 2.0 times the ULN in the absence of known hepatic metastases
+Aspartate aminotransferase (AST) > 45 U/L
+Alanine aminotransferase (ALT) > 45 U/L
+Aspartate aminotransferase (AST)/alanine transaminase (ALT) less than 2.5 X institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN (within 14 days of PET imaging)
+Aspartate aminotransferase (AST) =< 3 x ULN.
+Alanine aminotransferase (ALT) =< 3 x ULN.
+Aspartate aminotransferase (AST) level =< 2.5 x ULN
+Alanine aminotransferase (ALT) level =< 2.5 x ULN
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 3 x ULN
+Within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
+Within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless due to liver involvement)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 X ULN
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless demonstrated lymphoma involvement of the liver, performed within 14 days prior to day 1 of protocol therapy
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times the ULN range of each institution. With the following exceptions: subjects with documented liver metastases; AST and ALT < 5 x ULN.
+An aspartate aminotransferase (AST) level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN.
+Alanine aminotransferase (ALT) =< 3 x upper limit of normal.
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or < 5 times ULN in the presence of liver metastases obtained =< 14 days prior to study initiation
+STRATUM A: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN); for the purposes of eligibility the ULN of ALT and AST is 45 U/L
+STRATUM B: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility the ULN of ALT and AST is 45 U/L
+STRATUM C: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility, the ULN of ALT and AST is 45 U/L
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ? 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional ULN OR =< 5 x ULN for subjects with liver metastases
+Severely impaired renal or hepatic function (eg, serum creatinine level > 2 mg/dL [176.8 ?mol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum aspartate aminotransferase [AST] level >3 times the upper limit of normal [ULN], or serum alanine aminotransferase [ALT] level > 3 times ULN).
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5X upper limit of normal (UNL);
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X upper limit of normal (ULN) or < 5 X ULN in the presence of liver metastases
+AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN (measured within 28 days of registration)
+Alanine aminotransferase (ALT) =< 1.5 times upper limit of normal
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal
+Alanine aminotransferase (ALT) =< 3 x upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x institutional ULN (? 5 x ULN in the presence of liver metastases)
+Serum alanine aminotransferase (ALT) ?3 × upper limit of normal (ULN) (Grade ?1).
+Serum aspartate aminotransferase (AST) ?3 × ULN (Grade ?1).
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN (or ? 5.0 x ULN if hepatic metastases are present)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than five times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
+Obtained within 21 days prior to cycle 1, day 1: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 4 x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) < 3 x ULN unless considered due to leukemic involvement
+(ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)
+STUDY TREATMENT: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 × ULN.
+COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULN
+Obtained within 14 days prior to randomization/registration:  aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limits of normal
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 1.5 x institutional upper limit of normal (ULN) or if liver metastasis, =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x IULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN), within 2 weeks of registration
+Aspartate aminotransferase (AST) ? 1.5 x ULN
+Alanine aminotransferase (ALT) ? 1.5 x ULN
+Serum ALT/AST ? 2.5 x ULN
+aspartate aminotransferase (AST) <= 3.0 x ULN*
+alanine aminotransferase (ALT) <= 3.0 x ULN*
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
+Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
+Obtained within 28 days prior to registration: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3x the institutional ULN, except for people with liver involvement by their lymphoma, who may be included if AST/ALT ? 5x the institutional ULN
+Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN). In the case of known (i.e., radiological or biopsy documented) liver metastasis, serum transaminase levels must be < 5 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Obtained within 28 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+To be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 2.5 x ULN
+To be performed within 14 days prior to day 1 of protocol therapy: alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at the screening visit
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN or
+Aspartate aminotransferase (AST) =< 2.5 upper limit of normal (ULN)
+Alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN without liver metastasis; =< 5 x ULN with liver metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
+Adequate renal and liver function as indicated by: i. Creatinine ? 1.5 x upper-normal limit (ULN) ii. Total bilirubin ? 1.5 x upper-normal limit (ULN) iii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN iv. Alkaline phosphatase ? 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
+Within 3 days before the first dose of study drug: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN), < 5 x in patients with known liver metastases
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x institutional upper limit of normal (ULN), unless felt to be due to disease involvement
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 X upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
+Within 4 weeks before enrollment: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) if no hepatic metastasis =< 2.5 times x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper limit of normal as per local laboratory
+Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with liver involvement)
+Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 3.0 x ULN for the institution within 14 days of study registration
+Alanine aminotransferase (alanine aminotransaminase [ALT]) and aspartate aminotransferase (aspartate aminotransaminase [AST]) ? 2.5 x IULN
+Aspartate and Alanine Aminotransferase (AST and ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 7 days prior to first study treatment
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase and alanine aminotransferase concentrations of =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) within 14 days of registration
+ALT ?3 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN (obtained within three days prior to study treatment)
+Alanine aminotransferase (ALT) =< 2.5 x ULN (obtained within three days prior to study treatment)
+Alanine aminotransferase (ALT) =< 3 x ULN.
+Aspartate aminotransferase (AST) =< 3 x ULN.
+Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 5.0 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Within 28 days prior to enrollment: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) =< 2.5 x ULN within 14 days of study registration.
+Alanine aminotransferase (ALT) =< 2.5 x ULN within 14 days of study registration.
+Alanine aminotransferase (ALT) (SPGT) is ? 3 X ULN for age
+Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
+Obtained within 21 days prior to randomization/registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN.
+Aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Within 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is associated with leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN except for subjects with liver mets for whom ALT and AST should be =< 5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with documented metastatic disease to the liver).
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3x ULN unless considered due to leukemic involvement
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of institutional normal (within 14 days of study registration)
+Within 7 days before the first dose of study treatment: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (results within 7 days before study drug administration), =< 5 x ULN for patients with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 x upper limit of institutional normal reference range
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN (or > 5 x ULN for patients with concurrent liver metastasis)
+Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or < 5 x ULN if liver involvement
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the exception that patients with liver involvement: AST and/or ALT =< 5 x ULN
+have adequate hepatic function, defined as having a serum total bilirubin concentration ?1.5mg/d, or ?2 x the upper limit of normal (ULN) if associated with hepatobiliary metastases or Gilbert syndrome, and having serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations ?2.5 × ULN, or ?5 x ULN for patients with known hepatic metastases;
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? 2.5 × ULN or AST and ALT levels ? 5 x ULN for subjects with documented metastatic disease to the liver; patient with history of unconjugated hyperbilirubinemia with otherwise acceptable liver enzyme levels (as per above criteria) may have higher bilirubin levels
+No more than 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULN
+Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
+Alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) or ALT < 5.0 times ULN in the presence of liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN or, in the case of liver involvement by the primary disease AST/ALT =< 5 x ULN
+Serum alanine aminotransferase (ALT)/alanine aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Performed within 14 days of treatment initiation: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
+Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ?2.5 times the upper limit of normal (ULN), or ?5 times the ULN for patients with liver metastases;
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 X ULN for patients with liver metastases
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN within 14 days prior to Step 2 registration
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) levels ? 2 x institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN unless believed due to leukemic infiltration
+Within 14 days of the first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
+Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2.5 × ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 X upper limit of normal (ULN)
+Within 14 days prior to registration: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 times ULN at the time of screening
+Alanine aminotransferase (ALT) =< 3 x ULN.
+Aspartate aminotransferase (AST) =< 3 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal
+Within 14 days prior to cycle 1 day 1 of treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN (5.0 x ULN if liver involvement)
+Within 14 days prior to cycle 1 day 1 of treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN (5.0 x ULN if liver involvement)
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if related to leukemic involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the upper limit of normal; for patients with documented liver metastases, AST/ALT =< 5.0 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 times ULN
+Patients must have normal hepatic function (bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 2 times the upper limit of normal)
+Aspartate aminotransferase (AST) =< 2.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) < 5 x upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) obtained =< 14 days prior to registration\r\n* NOTE: if baseline liver disease, Child Pugh score not exceeding class A
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin =< 5 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
+alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ? 2.5 x ULN (? 5 x ULN if liver metastases are present);
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal, within 2 weeks of registration (except where specified otherwise)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN
+Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN, within 30 days before study registration
+Obtained within 14 days prior to enrollment: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 3 x institutional upper limit of normal (IULN) without liver mets or =< 5 x IULN with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) within 14 days prior to first dose
+(For both cohorts A and B): Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN and total bilirubin < 2.0 mg/dL unless due to malignancy or Gilbert’s syndrome in the opinion of the PI or designee
+Alanine aminotransferase and aspartate aminotransferase =< 2.5 X ULN except in patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation that is declared to be caused due to liver metastasis, they are allowed to be enrolled as long as < 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULN
+Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
+ALT (alanine aminotransferase) =< 2 x ULN
+AST (aspartate aminotransferase) =< 2 x ULN\r\n* NOTE: ALT and/or AST may be =< 5 x ULN if due to liver metastases. If ALT or AST is > 2 and =< 5 x ULN in patients with liver metastases
+Within 4 weeks prior to the registration: aspartate aminotransferase (AST) =< 3 X upper limit of normal
+Aspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 5 x ULN
+Aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal obtained < 4 weeks prior to starting treatment
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (=< 5 x institutional ULN if there is liver metastasis)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of institutional normal
+AST/ ALT ? 2.5x institutional ULN
+AST and ALT <2.5 x ULN
+Aspartate aminotransferase (AST) greater than 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) greater than 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjects
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 14 days of randomization: Aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 14 days of randomization: Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
+Determined within 3 weeks of treatment initiation: Aspartate aminotransferase (AST) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
+Determined within 3 weeks of treatment initiation: Alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
+aspartate aminotransferase (AST) ? 3.0 × ULN*
+alanine aminotransferase (ALT) ? 3.0 × ULN*
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN (> 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 5 x institution’s upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) (or < 5 x ULN if liver metastasis are present)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
+Aspartate aminotransferase (AST), level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) =< 2.5 x ULN prior to biopsy
+Alanine aminotransferase (ALT) =< 2.5 x ULN prior to biopsy
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
+Aspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN
+Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
+FULL STUDY INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)
+Alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x upper limit of institutional normal (ULN), within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
+Serum ALT/AST ? 2.5 ULN
+Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) >5 times ULN at screening, or total bilirubin >=3.0 x ULN at screening (except for documented Gilbert's syndrome), as analyzed by local or central lab.
+alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
+Hepatic: Active hepatitis (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or bilirubin > 2 times the upper limit of normal [ULN]) or evidence of moderate to severe periportal fibrosis by liver biopsy
+Aspartate aminotransferase (AST) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have AST =< 5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have ALT =< 5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be <= 2.5 * the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease in liver.
+Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 x the upper limit of normal (ULN); if the patient has liver metastases, ALT and AST should be < 5 x ULN
+Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x the institutional upper limit of normal (unless demonstrated Hodgkin lymphoma involvement of the liver); estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault) and/or 24 urine analysis as needed
+LYMPHODEPLETION: Aspartate aminotransferase (AST) =< 3.0 x ULN, obtained within 72 hrs prior to procurement
+LYMPHODEPLETION: Alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 72 hrs prior to procurement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, obtained =< 14 days prior to registration
+Within 14 days prior to planned start of treatment: Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)
+Within 14 days prior to planned start of treatment: Alanine aminotransferase (ALT) =< 2 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltration
+Aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) ?3.0 x ULN
+Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) less than or equal to 3 x ULN (unless due to B-ALL)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and AST <3x institutional ULN within 7 days prior to starting the study drug.
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x upper limit of institutional normal reference range
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN if no demonstrable liver metastases or =< 5 x ULN in the presence of liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
+AST and ALT ? 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN should be obtained within 21 days prior to enrollment
+Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml for adults; conjugated (direct) bilirubin < 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
+Aspartate aminotransferase (AST) =< 1.5 x ULN for the laboratory
+Alanine aminotransferase (ALT) =< 1.5 x ULN for the laboratory
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times ULN or =< 5 times ULN if patient has documented liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases
+Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present, within 14 days start of study start
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times upper limit normal
+In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver metastases, ALT and AST should be < 5 × ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 3 x ULN
+Alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) < 3 x ULN
+Alanine aminotransferase (ALT) =< 1.5 x ULN, aspartate aminotransferase (AST) =< 1.5 x ULN); ALT and AST =< 5 x ULN if documented liver metastases
+Serum alanine aminotransferase or aspartate aminotransferase < 3 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 1.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+AST and ALT < 2.5 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase < 3 times upper limit of laboratory normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\r\n* > 2.5 x ULN\r\n* > 5 x ULN, if liver metastasis present
+AST or ALT > 2.5 x ULN
+Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 5 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN (=< 5.0 x ULN if due to leukemic involvement)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN unless thought to be disease related
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN); for subjects with liver metastases, AST or ALT =< 5 x ULN
+Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) if no liver involvement or =< 5 x the ULN if documented liver involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X upper limit of normal (ULN)
+Aspartate aminotransferase (ALT)/alanine aminotransferase (AST) =< 2.5 times the upper limit of normal
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 X the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal if no liver involvement or =< 5 times the upper limit of normal with liver involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULN
+Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 x ULN for age
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 2.5 × upper limit of the normal reference range (ULN)
+Aspartate aminotransferase (AST) =< 2 x ULN for the laboratory
+Alanine aminotransferase (ALT) =< 2 x ULN for the laboratory
+Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects hepatic metastases, ALT and AST =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5 x ULN, within 14 day prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Liver function (total bilirubin <2mg/dL and aspartate aminotransferase and/or alanine aminotransferase <3 × upper limit of normal (ULN) or <5 × ULN if related to leukemic involvement)
+Liver function (total bilirubin <2mg/dL and aspartate aminotransferase and/or alanine aminotransferase <3 × upper limit of normal (ULN) or <5 × ULN if related to leukemic involvement)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal
+For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, gamma-glutamyl transferase (GGT) and alkaline phosphatase (AP).
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 times the upper limit of normal for age
+Aspartate transaminase (aspartate aminotransferase [AST]) > 3.0 x ULN
+Alanine transaminase (alanine aminotransferase [ALT]) > 3.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN; if liver metastases are present, then AST and ALT =< 5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 X ULN
+Alanine aminotransferase (ALT) =< 2.5 X ULN
+Aspartate aminotransferase (AST) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
+Alanine aminotransferase (ALT) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
+Aspartate aminotransaminase (AST), alanine aminotransaminase (ALT) within 2.5 x institutional upper limits of normal unless there are liver metastases in which case AST and ALT within 5.0 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (unless demonstrated Hodgkin lymphoma involvement of the liver); estimated creatinine clearance >= 30 ml/min (Cockcroft-Gault) and/or 24 urine analysis as needed
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) or 5.0 x upper limit of normal (ULN) in the setting of liver metastases
+Transaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 2.5 upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN and total bilirubin =< 2 x ULN
+Serum alanine transferase (ALT) and aspartate transaminase (AST) < 3 the upper limit of normal (ULN); < 5 ULN if there is liver involvement secondary to the tumor
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x upper limit normal (ULN), or =< 5 x ULN if documented liver metastases are present
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ? 3 x upper limit of normal (ULN) (? 5.0 x ULN if liver metastases present)
+PRIOR TO CELL PROCUREMENT: Aspartate aminotransferase (AST) ? 3 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x ULN
+Aspartate aminotransferase and/or alanine aminotransferase =< 3 x ULN (=< 5 x ULN if liver metastases are present) within 30 days prior to C1D1
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 4.0 x ULN if hepatic metastases are present)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) above 2.5 upper limit of normal (ULN)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
+Aspartate aminotransferase(AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal and bilirubin < 3 x upper limit of normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 3 times the upper limit of the institutional normal unless liver involvement by malignancy is demonstrated
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X IULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3x upper limit of normal
+DONOR: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); for subjects with liver metastasis, ALT and AST =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Serum ALT, AST ? 2 × ULN
+Aspartate aminotransferase (AST) =< 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the AST may be =< 5 x ULN
+Alanine aminotransferase (ALT) =< 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the ALT may be =< 5 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) must be < 5 x upper limit of normal unless related to disease
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 × ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 6 x upper limit of normal (ULN)
+Aspartate aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatment
+Alanine aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatment
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN obtained within 14 days prior to randomization/registration
+In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN; for patients with liver metastases: AST/ALT > 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (alanine transaminase) (ALT) < 3 x upper limit of normal (ULN)
+PHASE I: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
+Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal OR =< 5 x institutional upper limit of normal in cases of liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Alanine aminotransferase and/or aspartate transaminase =< 3.0 x ULN or =< 5.0 x ULN if deemed to be elevated due to leukemia
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN
+Aspartate aminotransferase =< 3 x ULN
+Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 times the upper limit of normal ([ULN]; or 5.0 times the ULN in the setting of liver metastases)
+Liver function abnormality as defined by total bilirubin >1.5 × ULN or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2.5 × ULN (except for subjects with liver involvement, who can have AST/ALT >5 × ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN if patients have liver involvement with MM)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X upper limit of normal (ULN)
+Within 3 months of registration: Aspartate aminotransferase (AST) =< 2.5 x ULN
+Within 3 months of registration: Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times ULN
+AST and ALT <3 x ULN
+ALT and AST ? 1.5 ULN
+Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 3 times the ULN
+Aspartate aminotransferase (AST) =< 3 times the ULN
+Within 14 days prior to study entry: Aspartate aminotransferase (AST) =< 3 x ULN
+Within 14 days prior to study entry: Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.0 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) for age
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 x ULN
+Aspartate aminotransferase (AST) of =< 3 times upper limit of normal
+Alanine aminotransferase (ALT) of =< 3 times upper limit of normal
+Within 6 weeks of day 1: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) all =< 2.5 x the institutional upper limit of normal (ULN)
+ARM A COHORT 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN); if liver metastases are present then must be < 5 X the ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 10 x ULN, unless related to ALL liver infiltration
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
+Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (or =< 5.0 x ULN if hepatic metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST) =< 3.5 x ULN
+Alanine aminotransferase (ALT) =< 3.5 x ULN
+AT THE TIME OF INFUSION: Aspartate aminotransferase (AST) ? 5 x normal
+AT THE TIME OF INFUSION: Alanine aminotransferase (ALT) ? 5 x normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
+alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN for subjects with liver metastases
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT =< 5 x ULN
+Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the ULN unless considered due to organ leukemic involvement
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal for age (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X the upper limits of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x the upper limit of normal (ULN)
+TREATMENT: Aspartate aminotransferase (AST) < 5 × ULN
+Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (must be within 7 days of MLA)
+Aspartate aminotransferase (AST) =< 3 x ULN (must be within 7 days of MLA)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.6 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x ULN, except patients who are assigned to receive docetaxel must have liver function tests (serum transaminases, bilirubin) that are within 1.5 x the ULN
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; patients with elevations of ALT or AST up to 10 times the upper limit of normal may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if AST/ALT do not decrease to less than or equal to 2.5 times the upper limit of normal after induction chemotherapy, eligibility for the transplant (research) phase will be at the discretion of the PI
+Must be met within 28 days of C1D1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x UNL (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) for the laboratory
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 3 times the institutional upper limit of normal
+Aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
+EXCLUSION CRITERIA FOR ENROLLMENT: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
+EXCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be less than or equal to (<=) 2.5*the ULN.
+Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 1.5 x ULN (< 5 x ULN if patient has liver metastasis)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit or normal (ULN) (stenting to improve biliary obstruction is permitted)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times above the ULN, ALT and AST can be < 5 times ULN if patients have hepatic involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < or =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x the ULN prior to biopsy
+Within 4 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+TREATMENT: Aspartate aminotransferase (AST) ? 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, obtained within 30 days of study registration
+Aspartate aminotransferase (AST) =< 1.5 x ULN, obtained =< 14 days prior to registration
+Alanine aminotransferase (ALT) < 3 times upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
+aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN ^1
+Within 21 days prior to C1D1: Aspartate aminotransferase (AST) < 2.5 times ULN and alanine aminotransferase (ALT) < 2.5 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN) or =< 5 x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) < 2.5 times upper limit of normal, performed within 28 days prior to registration
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limits of normal
+Aspartate aminotransferase (AST) < 5 times the upper limit of normal
+Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy
+Within 2 weeks of enrollment: Alanine aminotransferase (ALT) =< 3 x normal range
+Within 2 weeks of enrollment: Aspartate aminotransferase (AST) =< 3 x normal range
+Aspartate aminotransferase (AST), and/or alanine aminotransferase (ALT) > 2 x the upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Patients must have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limits of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN
+If the research participant is to undergo leukapheresis, he/she must have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limits of normal\r\n* Note: in the event a patient has elevated levels of liver enzymes possibly related to underlying disease, the patient will still be considered eligible
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × the upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase/alanine aminotransferase of =< 2.5 × upper limit of normal
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if related to leukemic involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present (to be performed within 7 days prior to start of study treatment)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) =< 3 times upper limit of normal, unless these are thought to be due to AML
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 X ULN, or for subjects with liver involvement AST and/or ALT > 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver involvement
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< twice the upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (UNL)
+Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) are equal or greater than 2 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4x ULN, unless secondary to disease
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Aspartate aminotransferase (AST) < 5 times the upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal range
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 121 IU/L
+Alanine aminotransferase (ALT) =< 189 IU/L
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULN
+Serum alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3.5 times the upper limit of normal in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert’s), within 14 days prior to starting therapy
+Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal or less than 200 IU/ml for adults
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) obtained within 2 weeks prior to registration
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x the upper limits of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; and
+Aspartate aminotransferase and alanine aminotransferase < 2.5 x ULN
+RECIPIENT: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) < 3 x upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 10x upper limit of normal
+Within 14 days of enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN, unless there are liver metastases in which case AST and ALT or > 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) for the laboratory
+Alanine aminotransferase (ALT) =< 5 times the upper limit of normal for age
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT ) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with liver involvement of leukemia)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X the upper limit of institutional normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 4 x normal
+Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
+Alanine aminotransferase (ALT) less than 2 x upper limit of normal
+Aspartate aminotransferase (AST) less than 2 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine and aspartate transaminases (ALT and AST) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
+Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN)
+Adequate hepatic function as defined by the following criteria:\r\n* Total serum bilirubin =< 1.5 x upper normal limit (ULN), unless due to Gilbert’s syndrome\r\n* Alanine aminotransferase (ALT) =< 2.5 x ULN\r\n* Aspartate aminotransferase (AST) =< 2.5 x ULN
+Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
+< 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN for patients without liver metastasis, =< 5 x ULN for liver metastases
+Aspartate aminotransferase (AST) =< 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x the upper limit of normal
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3.0 x the institutional upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3 x ULN unless considered due to leukemic involvement
+Serum alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Serum aspartate aminotransferase (AST) =< 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 X the upper normal limit of institution's normal range
+Alanine aminotransferase (ALT) =< 2 times the ULN or aspartate aminotransferase (AST) =< 2 times the ULN; these values must be obtained within four weeks before protocol entry
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Total bilirubin >1.5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN at screening
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 x ULN if due to lymphoma involvement, without use of growth factor support for 1 week
+Patients must have adequate hepatic function as evidenced by total serum bilirubin ? 1.5 x the upper limit of normal (ULN) and a prothrombin time (PT) within 2 seconds of the upper normal limit. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) must be ? 2.5 x ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × ULN or < 5 × ULN in the setting of liver metastases
+Alanine aminotransferase (ALT) > 3 x ULN
+Aspartate aminotransferase (AST) > 3 x ULN
+Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ?5 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Patients with alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 3 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Alanine aminotransferase (ALT) must be < 2 times upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
+Adequate hepatic function with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal for age
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
+Aspartate aminotransferase (AST) > 5x upper limit of normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
+< 3 x upper limit of normal (ULN) aspartate aminotransferase (AST)
+Aspartate aminotransferase (AST) =< 2 x upper limit of normal
+Alanine aminotransferase (ALT) =< 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limits of normal
+Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) < 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 3 X normal\r\n* If AST and ALT are > 3 < 5 x upper limit of normal (ULN), patient may be eligible if:\r\n** Liver biopsy performed within 60 days of hematopoietic cell transplantation (HCT) excludes active cirrhosis grade greater than 2/4 and bridging fibrosis\r\n** No clinically evident ascites\r\n** Patient with hepatitis B or C are excluded if AST or ALT > 3 x upper limit (UL)
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal within 7 days prior to starting treatment in the absence of liver metastasis; in the presence of liver metastasis serum AST and ALT less than or equal to 5.0 times the upper limits of normal within 7 days prior to starting treatment
+Patients with organ dysfunction will not be excluded from the study; for patients with evidence of organ dysfunction (creatinine >= 1.5, cardiac ejection fraction =< 50%, total bilirubin >=2 and aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 3 times upper limit of normal [ULN]), dose adjustments/omissions will be made
+Alanine aminotransferase (ALT) < 3 x upper limit of normal unless benign congenital hyperbilirubinemia
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 4x normal
+Alanine aminotransferase (ALT) < 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x normal
+Bilirubin, aspartate aminotransferase (AST)/alanine aminotransferase (ALT), alkaline phosphatase (ALP) =< 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (AST and ALT =< 6 x ULN for patients on hyperalimentation for whom these abnormalities are felt to be due to the hyperalimentation)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)? 2.5 × upper limit of normal (ULN) (if liver metastases are present, then?5 x ULN is allowed)
+Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 1.5 × ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN without liver metastases (or ? 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) < 3 times the ULN
+Alanine aminotransferase (ALT) ?110 units per Liter (U/L). For the purpose of this study, the ULN for ALT is 45 U/L
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 x ULN.
+Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement), obtained =< 14 days prior to registration
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver metastases)
+alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal (ULN),
+Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase level (<=) 2.5* ULN, and
+Aspartate aminotransferase (AST) < 4 times the upper limit of institutional normal
+Alanine aminotransferase (ALT) > 2.5 X ULN or cirrhosis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ? 3 x ULN
+AST < 3.0 x ULN
+ALT < 3.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (repeat if more than 3 days before the first dose)
+Alanine aminotransferase (ALT) within the reference range during screening evaluation
+Aspartate aminotransferase (AST) within the reference range during screening evaluation
+Alanine aminotransferase (ALT) > 5 x ULN
+Aspartate aminotransferase (AST) > 5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x ULN Inclusion Criteria unique to the ER+ve cohort:
+Aspartate aminotransferase and alanine aminotransferase ? 3 × upper limit of normal
+Adequate baseline laboratory data: hemoglobin >9 g/dL, absolute neutrophil count (ANC) ?1,000/µL, CD4+ T-cells ?200/µL, platelets ?50,000/µL, bilirubin ?1.5 X upper limit of normal (ULN) or ?3 X ULN for patients with Gilbert's disease, serum creatinine ?1.5 X ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?3 X ULN.
+Patients with serum aspartate aminotransferase, alanine aminotransferase > 2.5 X the upper limit of normal (ULN) and bilirubin >1.5 ULN
+Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULN
+Alanine aminotransferase (ALT) =< 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT =< 2.5 times ULN is acceptable
+Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3.0 × upper limit of normal (ULN); if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) ? 5 × ULN.
+Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institution
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; NOTE: concomitant elevations in ALT/AST above 1.0 x ULN is not permitted
+Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3x upper limit of normal within institutional limits; bilirubin ? 1.5 mg/dl
+AST / ALT (SGPT) <2.5 x ULN
+AST and ALT ? 1.5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional ULN or =< 5 x the institution ULN in the presence of known liver metastases
+Aspartate aminotransferase (AST) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) must be no more than 2.5 times upper limit of normal unless due to disease involvement of the liver
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and Alkaline Phosphatase (ALP) must be within the range allowing for eligibility: ALP normal AND AST or ALT =< 5 x ULN; ALP =< 3.5 x ULN AND AST or ALT =< 1.5 x ULN; OR ALP =< 5 x ULN AND ALT or AST =< ULN
+Hepatic: bilirubin <1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
+109 Laboratory parameters (completed within 14 days prior to enrollment): Hematology: Absolute neutrophil count (ANC) ? 1.0 x 10^9/L, Platelets ? 75 x 10^9/L. Chemistry: Creatinine clearance ? 50 mL/min (calculated using Cockcroft Gault equation). Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3X upper limit of normal (ULN), Total bilirubin (TBL) < 2x ULN (unless Gilbert's disease or if liver involvement with lymphoma)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5x ULN
+Within 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if known hepatic metastases
+Within 14 days prior to randomization: Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) must be =< 2.5 x ULN for the lab or =< 5 x ULN for patients with liver metastases.
+AST and ALT <3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Aspartate aminotransferase (AST/ SGOT) and alanine aminotransferase (ALT/ SGPT) < 3 x the upper limits of normal (ULN)
+Aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) < 3 x ULN
+To be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 3 x ULN\r\n* If hepatic involvement by lymphoma: AST =< 5 x ULN
+To be performed within 14 days prior to day 1 of protocol therapy: alanine aminotransferase (ALT) =< 3 x ULN\r\n* If hepatic involvement by lymphoma: ALT =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN
+Aspartate aminotransferase and alanine aminotransferase ?2.5 × ULN
+Within 14 days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase AST, alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ? 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with suspected liver involvement of leukemia)
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be =< 5 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) or =< 5 x ULN if documented liver metastases.
+Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit normal (ULN)
+Obtained ? 14 days prior to registration: aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 3 x ULN
+Alanine aminotransferase/aspartate aminotransferase (ALT/AST) =< 5 x ULN.
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN if patient has liver metastasis
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > 3 times the upper limit of normal (x ULN); patients with values > 3 x ULN and < 5 x ULN are eligible if the value is acute and directly related to the infectious process being treated
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULN
+Within 14 days prior to first dose of study drug treatment: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver metastases: AST and/or ALT =< 5 x ULN
+BLADDER: Clinical laboratory values at screening: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULN
+Within 7 days before the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransfearse (AST) =< 2.0 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 3.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x upper limits of normal (ULN) if liver metastases are present =< 14 days prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x upper limit of normal\r\n(ULN); for subjects with liver metastasis, ALT and AST </= 5 x ULN within 3 weeks prior to initial treatment
+Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN).
+Aspartate aminotransferase (AST) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
+Alanine aminotransferase (ALT) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 28 days of day 0.
+Within 10 days of treatment initiation: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x the upper limit of normal.
+Within 14 days of study registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X the upper normal limit of institution's normal range
+Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Aspartate aminotransferase (AST) =< 2 x ULN
+Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine aminotransferase (ALT) =< 2 x ULN
+Alanine aminotransferase (ALT) < 3 times the upper limit of institutional normal
+Within 14 days of study registration (30 days for pulmonary and cardiac): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of institutional normal
+Aspartate aminotransferase (AST) < 2.5 times upper limit of normal
+Aspartate transaminase (AST) and alanine aminotransaminase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal, unless bone or liver metastasis is present (=< 5 x upper limit of normal)
+At cycle 1 day 1 pre-dosing: Alanine aminotransferase level (ALT) >= 2.5 x the upper limit of normal (ULN)
+At cycle 1 day 1 pre-dosing: Aspartate aminotransferase (AST) >= 2.5 x the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase, alanine aminotransferase (AST, ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
+Subjects with aspartate aminotransferase (AST) or alanine transaminase (ALT) >= 2 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than or equal to 2.5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase < 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
+Alanine aminotransferase (ALT) =< 3 x the upper limit of normal unless considered due to leukemic involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if there is evidence of hepatic involvement by malignant disease)
+Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) =< 2.5 times the ULN except in patients with hepatic metastases for whom AST and ALT must be < 5.0 times the ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferease (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 upper limit of normal (ULN)
+Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) < 2 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with liver metastases may enroll with AST and ALT =< 5 x ULN
+Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
+Transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) < 6 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × the upper limit of normal (ULN).
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases obtained =< 28 days prior to registration
+Have serum aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) > 5 times ULN at screening, or total bilirubin >= 3.0 x ULN at screening (except for documented Gilbert's syndrome), by local or central lab. Subjects with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT > 5 times ULN at screening.
+Aspartate aminotransferase (aspartate transaminase [AST]) =< 2.5 x ULN, obtained =< 7 days prior to registration
+Alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN, obtained =< 7 days prior to registration
+Serum aspartate transaminase (alanine aminotransferase [ALT]) and/or aspartate transaminase (aspartate aminotransferase [AST]) values < 3 x the upper limit of normal (ULN) of the local laboratory reference range; patients with elevated bilirubin due to Gilbert’s syndrome may be permitted with principal investigator (PI) approval
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1
+Aspartate aminotransferase (AST) must be =< 3 x ULN for the lab within 28 days before randomization;\r\n* Note: if alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 3 x ULN; if both were performed, the AST must also be =< 3 x ULN; if AST and/or ALT is >= ULN but =< 3 x ULN, serologic testing for hepatitis B and C must be performed and results for viral infection must be negative
+Alanine aminotransferase and aspartate aminotransferase =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limits of normal
+Within 14 days prior to step 1 registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels >= 2.5 times the ULN or >= 5 times the ULN if liver metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
+Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
+Subject has a total bilirubin ? 1.5 x upper limit of normal (ULN), albumin ? 2.5 g/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each < 1.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN); however, in the presence of liver metastases or in patients with refractory leukemias, AST and ALT must be < 5 x ULN
+Aspartate transaminase (AST)/alanine transferase (ALT) < 3.0 ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registration
+ARM A: obtained =< 14 days prior to registration: \r\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal
+Obtained within 30 days prior to registration: Aspartate aminotransferase (AST) =< 1.5 x ULN
+Obtained within 30 days prior to registration: Alanine aminotransferase (ALT) =< 1.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN in case of liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x IULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3 times the institutional upper limit of normal
+Aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
+Liver disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limits of normal, unless determined to be a result of the primary hematologic malignancy
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 3 times upper limit of institutional normal
+Alanine aminotransferase (ALT) > 50 U/L or aspartate aminotransferase (AST) > 65 U/L
+Aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the ULN if no liver involvement, or =< 5 x the ULN with liver involvement
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN)
+AST/ALT < 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 3.0 x ULN
+Within 14 days of registration: Aspartate aminotransferase (AST) =< 5 x upper limit of normal
+Within 14 days of registration: Alanine aminotransferase (ALT) =< 5 x upper limit of normal
+Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) within 2 weeks before baseline
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< or = 2.5 X institutional upper limit of normal (ULN).
+In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST =< 5.0 x institutional ULN
+Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to Step 2 re-registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5.0 x ULN
+Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to Step 2 re-registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN in subjects without liver metastases or =< 5.0 times ULN in subjects with liver metastases
+Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to step 2 re-registration (if both ALT and AST are done, both must be < 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
+Aspartate aminotransferase (AST) < 1.5 X upper limit of normal (ULN); patients with Gilbert's disease are exempt from this criteria
+Alanine aminotransferase (ALT) < 1.5 X ULN; patients with Gilbert's disease are exempt from this criteria
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< upper limit of normal (or < 3.0 x ULN if liver metastases are present)
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
+Transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) =< 3.0 x upper limit of normal (ULN) unless due to leukemia infiltration
+Aspartate aminotransferases (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times institutional upper normal level (AST and ALT =< 5 times institutional upper normal level, if there is evidence of liver metastasis)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 upper limit of normal (ULN) or =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, the AST/ALT =< 5 times ULN is acceptable
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 3 x ULN for the laboratory
+Alanine aminotransferase (ALT) =< 3 x ULN for the laboratory
+AST (aspartate aminotransferase) and ALT (alanine aminotransferase) < 3 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x UNL unless related to primary disease
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x the upper limit of normal, within 14 days prior to registration
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of the institutional normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for the institution
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper limit of normal (ULN) within 14 days prior to admission
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to metastatic breast cancer to the liver (in which case AST/ALT < 5 x ULN is allowed)
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal; NOTE: adult values will be used for calculating hepatic toxicity and determining eligibility, as is standard on POB phase I trials
+Aspartate aminotransferase (AST) < 2.5 x ULN of the institutional normal reference range
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 4 x institutional upper limits of normal (IULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN within 14 days of enrollment
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN, within 2 weeks of the first dose of study treatment
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 times institutional upper limit of normal (IULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the institutional upper limit of normal
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within 5 times the upper limit of normal
+Aspartate aminotransferase (AST) less than 5 times the upper limit of normal
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 3.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with documented liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal value (unless elevation is determined by the treating physician to be related to involvement by underlying cancer)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) for patients with liver metastases and =< 2.0 x ULN for patients without liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X institutional upper limit of normal
+Transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) > 20 x ULN based on age- and laboratory specific normal ranges
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x ULN (with or without liver metastasis [mets])
+Aspartate aminotransferase (AST) < 2.5 times upper limit of normal
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x institutional ULN; note: patients who have both bilirubin > ULN and AST/ALT > ULN are not eligible (unless they have Gilbert's syndrome and elevations of indirect bilirubin)
+Aspartate aminotransferase (AST) =< 3.0 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN (unless elevated due to secondary lymphomatous involvement of the liver)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
+Alanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (=< 5 x institutional upper limit of normal if evidence of liver metastasis)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 times the upper limits of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limit of normal
+AST/ALT =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 times upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must each be =< 3-times the upper limits of normal (ULN) or =< 10-times normal if due to ATL
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Aspartate aminotransferase (AST) =< 5 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALK PHOS) must be within the range of eligibility as noted below:\r\n* AST or ALT =< 5 x ULN and ALK PHOS =< ULN\r\n* AST or ALT =< 1.5 x ULN and ALK PHOS =< 2.5 x ULN\r\n* AST or ALT =< ULN and ALK PHOS =< 5 x ULN
+Aspartate aminotransferase (AST) less than 5 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 2 times the upper limit of normal
+No history of severe prior or ongoing chronic liver disease; aspartate aminotransferase (AST) < 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times upper limit of normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times upper limit of normal; values above these levels may be accepted, at the discretion of the PI or LAI, if such elevations are thought to be due to liver involvement by malignancy or GVHD
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 x upper limit of normal
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x IULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 3 x laboratory upper normal limits
+Serum aspartate aminotransferase and alanine aminotransferase ? 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN; in the setting of metastatic disease to the liver, AST/ALT may be =< 5 x ULN
+Alanine transaminase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal
+ALT or AST <3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 2.5 times upper limit of normal
+Total bilirubin ?1.5 × the upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal, unless due to liver metastases (=< 5 x ULN)
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3.0 x upper limit of normal (ULN);
+Aspartate and alanine aminotransferase (AST & ALT) ?3.0 x ULN or ?5.0 x ULN if subject has liver metastasis;
+Subjects must have adequate hepatic function as evidenced by: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin ?1.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic disease
+Patients must have aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x IULN, unless due to lymphoma, within 42 days prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN (or 5.0 x ULN in the setting of liver metastases)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patients with hepatic metastases: ALT and AST =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (if both tests are done, both results need to be =< 2.5 x ULN)
+Aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 times upper limit of normal (ULN) or =< 5.0 times the ULN in the setting of liver metastases
+Patient must have adequate hepatic function as evidenced by: Serum total bilirubin ?1.5 × upper limit of normal (ULN), unless considered due to Gilbert's disease or disease involvement; Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For patients with bone metastases and/or suspected disease-related liver or biliary involvement, AST, ALT and ALP must be ?5 × ULN
+Alanine Aminotransferase (ALT) < 5 times the upper limit of normal (ULN) for age;
+Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
+CLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases); these results must be obtained within 28 days prior to registration
+Serum/plasma alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.
+Alanine Aminotransferase (ALT) ? 5 times the Upper Limit of Normal (ULN) for age
+Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ? 2.5 x Upper Limit of Normal (ULN) or ? 3.0 x ULN if liver tumor is present,
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.0 * upper limit of normal (ULN).
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (institutional)
+Total bilirubin =< 1.5 x IULN or =< 3.0 x IULN with normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in patients with Gilbert’s disease
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
+Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to RE-TREATMENT registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 x IULN
+Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 2.5 upper limit of the normal range (ULN) (or ? 5 if hepatic metastases are present)
+Alanine Aminotransferase (ALT) ? 5 times the upper limit of normal (ULN) for age.
+Total bilirubin > 1.5 x ULN; and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 times the upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN
+AST <3 × ULN
+allow alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5x upper limit of normal (ULN) if liver metastases.
+Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN; patients with liver metastases may have AST and ALT of =< 5.0 x IULN
+Serum aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) > 2.5 × upper limit of normal (ULN)
+Subject has total bilirubin (TBL) ? 1.5 x the upper limit of normal (ULN) (except subjects with documented Gilbert's disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 x the ULN .
+Aspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis), obtained =< 21 days prior to registration
+AMKL PATIENTS: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) > 2.5 x Upper Limit of Normal (ULN), total serum bilirubin > 1.5 x ULN (patients with Gilbert's Disease may be included if their total bilirubin is ?3.0 mg/dL)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without liver metastases
+Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) ? 2.5 x upper limit of normal (ULN), total bilirubin ? 1.5 x ULN, creatinine ? 2.0 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 times the ULN if no liver metastases; for patients with known liver metastases, AST and ALT must be =< to 5 times the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 X IULN in the absence of liver metastases or =< 5.0 x IULN with liver metastasis
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases and =< 5 x ULN for patients with liver metastases
+Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN) or =< 5 x ULN if liver involved by lymphoma
+Aspartate aminotransferase (AST) =< 1.5 X upper normal of limit (UNL)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
+Hepatic: Aspartate aminotransferase/Alanine aminotransferase <3X upper limit of normal (ULN); Total bilirubin <2X ULN (unless Gilbert's Disease or if liver involvement with lymphoma)
+Serum/plasma alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
+Asparate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 2 x ULN for the lab. (Note: If AST and/or ALT greater than ULN, serologic testing for Hepatitis B and C must be performed and results must be negative.)
+SUB-PROTOCOL AIM A: Aspartate transaminase (AST); alanine aminotransferase (ALT) =< 1.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal (ULN)
+aspartate aminotransferase, alanine aminotransferase ? 2.5 X ULN, or ? 5.0 X ULN (if liver metastasis present)
+Aspartate aminotransferase (AST) ? 2.0 X ULN,
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN) and bilirubin =< ULN for patients without liver metastases
+Aspartate aminotransferase (AST) ? 2 x ULN
+Alanine aminotransferase (ALT) ? 2 x ULN
+Hepatic: Total bilirubin ? 1.5 x the upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ? 3.0 x ULN OR ? 5.0 x ULN for patients with liver metastases.
+Alanine aminotransferase (ALT) =< 3 x ULN within 14 days prior to study registration
+Aspartate aminotransferase (AST) =< 3 x ULN within 14 days prior to study registration
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULN OR ALT and AST =< 5.0 x IULN for patients with documented hepatic involvement with NHL
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit normal (ULN)
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR or alkaline phosphatase (ALP) > 2.5 x ULRR
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x institutional normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) unless liver metastases documented; in this latter case, AST and ALT < 5 x ULN required
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times above the upper limits of the institutional norm; ALT, AST can be < 5 times upper limits of normal if patients have hepatic involvement
+Aspartate aminotransferase (AST) =< 2.5 x ULN or alanine aminotransferase (ALT) =< 2.5 x ULN (Note, if both AST and ALT are done, both must be =< 2.5 x ULN) OR
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3.0 × the upper limit of normal (ULN).
+Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) superior to 3 x ULN.
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasis
+Alanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasis
+Screening chemistry values of the following: alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal reference range (ULN), total bilirubin ? 2 × ULN, creatinine ? 1.5 × ULN, fasting blood glucose < 140 mg/dL, hemoglobin A1C ? ULN, albumin ? 2.8 g/dL.
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (<=) 2.5*the upper limit of normal (ULN);
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5*ULN.
+Hepatic function: serum albumin >3.0 g/dL; aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) <3x the upper limits of normal (ULN); alkaline phosphatase <2x the ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5X institutional upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+ALT and AST ?3 x ULN or ?5 x ULN if known hepatic metastases.
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ? 2.5 x ULN
+Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
+Within 14 days of study start: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN) or =< 5.0 x ULN if liver tumor is present
+Aspartate aminotransferase less than or equal to 3 x ULN
+Alanine aminotransferase less than or equal to 3 x ULN
+AST and/or ALT >3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Serum alanine aminotransferase < 3 times the upper limit of normal (ULN); Note: If elevated liver enzymes are related to disease alanine aminotransferase (ALT) should be < 5 times ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN, or =< 5.0 x ULN for patients with documented hepatic involvement
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3x upper limit of normal
+Aspartate aminotransferase (AST) > 1.5 x institutional upper limit of normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than three times the upper limit of normal
+If liver metastases present, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be < 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < or equal to 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (IULN) or =< 5 x IULN if liver metastases are present
+Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 x the institutional normal upper limit
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
+Hepatic: Bilirubin 1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
+Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Platelet Count ? 50 x 10^9/L (? 100 x 10^9/L if aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is ? 2 x the upper limit of the normal range [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days
+Aspartate aminotransferase (AST) or alanine aminotransferase (AST) =< 2.5 x upper limits of normal except if due to disease infiltration of the liver
+Alanine aminotransferase (ALT) =< 2.5 times the UIHC upper limit of normal
+Aspartate aminotransferase (AST) =< 2.5 times the UIHC upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (Exception: =< 5 x ULN, if elevation is considered related to ASM/MCL)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT ) =< 2 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN in the presence of liver metastases)
+Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) less than or equal to 5 X the upper limit of normal (ULN)
+Adequate hepatic function defined as: total bilirubin ?2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 times the institutional ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X institutional upper limit of normal; subjects with known liver involvement by lymphoma: AST/ALT =< 2 X institutional upper limit of normal
+Aspartate aminotransferase (AST) < 5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) obtained within 4 weeks prior to registration
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x the upper limit of normal
+Aspartate aminotransferase (AST) 3 times or less than the upper limit of normal
+Serum alanine aminotransferase (ALT)/serum aspartate aminotransferase (AST) < 2.5 X ULN (the upper limit of normal)
+Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN, if documented liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+AST and ALT ? 3.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (unless the transaminitis is considered to be related to MF)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 if due to lymphoma involvement
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present (within 14 days prior to day 1 of protocol therapy)
+(ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal)
+AST and ALT ?2.5 × institutional ULN. Patients enrolled in an expansion stage may have ALT and AST <5 × institutional ULN if the patient has hepatic metastases.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULN
+Hepatic: total bilirubin ? 2.5 mg/dL, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) < 5 x upper limit of (ULN) (unless disease related)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
+Have adequate hepatic function (bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), defined as ? 2 times the upper limit of normal [ULN])
+Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
+Serum ALT/AST ? 2.5 x ULN
+ALT > 3 x ULN
+AST > 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) within 3 times the upper limits of normal
+Alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 upper limit of normal or > 250 U/l
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< upper limit of normal (ULN)
+AST, ALT must be <2 x ULN.
+Prior to cyclophosphamide and T cell infusions: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN (since all patients will have liver metastasis)
+In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN). If the patient has liver metastases, ALT and AST < 5 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) less than or equal to 3 times institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases =< 7 days prior to randomization
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 2.5 x ULN if no liver metastases or ALT or AST up to 5 x ULN if liver metastases present
+Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) in the case of liver metastases or AST/ALT =< 1.5 x ULN in patients without liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Within 72 h of initiating study treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for liver metastases (mets)
+Within 72 h of initiating study treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN for liver mets
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN (or =< 3 x ULN if liver involved with disease
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
+Adequate bone marrow, hepatic, renal and coagulation function as defined by the following: Absolute neutrophil count ?1.5 x 10^9/L, Hemoglobin ?9.0 g/dL (90 g/L), Platelets ?100 x 10^9/L, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT ?5 x ULN, Bilirubin ?1.5 x ULN, Prothrombin time (PT) / international normalized ratio (INR) ?1.5 x ULN, Calculated creatinine clearance >50 mL/min using the Cockcroft and Gault equation
+Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (=< 5 x ULN for patients with liver involvement)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (values post biliary stenting allowed for eligibility)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
+Aspartate aminotransferase (AST) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
+Alanine aminotransferase (ALT) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper normal limit (=< 5 x upper normal limit if documented hepatic involvement with lymphoma)
+Hepatic: Serum total bilirubin <=1.5 x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if their total bilirubin is <= 3.0 mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 2.5 x ULN. If the patient has known liver metastases, an ALT and/or AST <= 5 x ULN are allowed.
+Aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 3 x upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
+AST or ALT > 5 x ULN
+Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine transaminase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Obtained within 14 weeks prior to registration on study: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
+Alanine aminotransferase (ALT) =< 3.5 times the upper limit of normal, unless due to chronic GVHD
+Transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) =< 2.0 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Has adequate hepatic function defined as total bilirubin ?1.5 mg/dL, unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin or ? 2 ULN. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × upper limit of normal (ULN) or ? 5 x ULN for subjects with known hepatic metastases.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 4.0 x ULN obtained within 14 days prior to registration
+Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.
+AST/ALT: ? 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/L
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 × ULN
+Aspartate aminotransferase (AST) =< 1.5 X ULN
+Alanine aminotransferase (ALT) =< 1.5 X ULN
+Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) < 2 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) obtained =< 14 days prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 5 x upper limits of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) > 2.5 x ULN
+AST or ALT ?2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+AST/ALT ? 1.5 × ULN
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 institutional upper limit of normal (IULN) (=< 5 x IULN if liver metastases are present)
+and aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Serum alanine aminotransferase ([ALT]; serum glutamate-pyruvate transferase [SGPT]), or serum aspartate aminotransferase [AST] where available at the center) < 2.5 x upper limit of normal (ULN), OR < 5 x ULN in the presence of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.0 x the institutional upper limit of normal (ULN), or, in patients with known liver metastases, ?5.0 x the institutional ULN.
+Inadequate liver function: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 3 liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >5× upper limit of normal [ULN] for >2 weeks; bilirubin >3× ULN) unless due to underlying disease
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 times the ULN, unless subjects have liver metastasis, in which case both AST and ALT must be less than or equal to 5 times the ULN
+Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 2.5 x ULN (for patients with liver metastases, =< 5 x ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) obtained =<14 days prior to randomization
+aspartate aminotransferase (AST) less than or equal to 2.5 × upper limit of normal (ULN)*
+alanine aminotransferase (ALT) less than or equal to 2.5 × ULN*
+Obtained =< 21 days prior to registration: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)
+Obtained =< 21 days prior to registration: Alanine aminotransferase (ALT) =< 3 x institutional ULN
+AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper limit of the normal range within 21 days prior to study registration
+Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (less than or equal to 5 x upper limit of normal for patients with liver involvement of their cancer)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 x ULN if no liver involvement or =< 4 x the ULN if known liver involvement
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
+Aspartate transaminase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x institutional upper limit of normal (IULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 times upper limit of normal (ULN); (for patients with liver involvement: AST and ALT =< 2.5 ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
+Alanine aminotransferase; and, Aspartate aminotransferase AST and ALT<=2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, ALT/AST must be =< 5 x ULN
+Alanine aminotransferase (ALT) < 2.5 times ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 * ULN.
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) ? 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
+Alanine aminotransferase (ALT) ? 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 upper limit of normal within 30 days prior to registration
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal; note: if hepatic function is abnormal, the decision to initiate temozolomide treatment should carefully consider the benefits and risks for the individual patient
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN), or =< 5.0 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
+Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN unless disease related.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary disease
+Alanine aminotransferase (ALT) < institutional upper normal limit
+Alanine aminotransferase and aspartate aminotransferase ?2.5 x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 × IULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 times the upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ?2.5 x upper limit of normal (ULN; ?5 x ULN is acceptable if liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For subjects with bone metastases and/or suspected disease-related liver or biliary involvement, ALP must be ?5 × ULN.
+AT THE TIME OF INFUSION: Aspartate aminotransferase (AST) ? 5 x upper limit of normal
+Total bilirubin level ?1.5 times institutional upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase ?2 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT may be =< 5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limit of normal
+alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4x upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 3.5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 2.5 X the upper limit of normal
+Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN unless disease related.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 2.5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
+COHORT A: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+COHORT B: AST/ALT =< 2.5 x ULN
+Serum alanine aminotransferase or aspartate aminotransferase < 3 times upper limit of normal (ULN)
+Serum alanine aminotransferase or aspartate aminotransferase > 3 times ULN
+The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not be more than 2.5 x ULN within 72 hours prior to enrollment, or greater than 5.0 X ULN if in the Investigator’s judgment it is related to liver metastases; AST and ALT may be up to 5 x ULN within 72 hours prior to enrollment in participants with hepatic metastases
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times upper level of normal (ULN)
+Aspartate aminotransferase (AST) and/ or alanine aminotransferase (ALT) should be =< 2 x upper limit of normal (ULN, defined as per laboratory where blood testing is done)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must each be =< 2.5 x the upper limits of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the upper limit of normal
+Subject's total bilirubin is ? 1.5 x upper limit of normal (ULN) (except for subjects with documented Gilbert's disease) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is ? 2.5x upper limit of normal (ULN) at Screening.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN unless associated with hepatic metastases, then ALT and AST ? 5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
+Aspartate aminotransferase (AST) =< 2.5 x ULN, alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x the upper limit of institutional normal
+Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 1.5 X upper limit of normal (ULN)
+Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (tested within 14 days prior to registration)\r\n* Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
+Alanine aminotransferase (ALT) ? 5 × institutional ULN
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x institutional upper limit normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the institutional upper limit of normal within 4 weeks of enrollment
+Within 30 days prior to initiation of protocol treatment: Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Within 30 days prior to initiation of protocol treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN) (< 5 x ULN if subject has liver metastases [mets])
+Adequate hepatic function, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); aspartate aminotransferase measurement (AST) and alanine aminotransferase measurement (ALT) ? 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ? 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (=< 5.0 x ULN if liver metastases are involved)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x the upper limit of normal within 30 days prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase and/or aspartate aminotransferase ?2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
+Alanine amino transferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (upper limit of normal); concomitant elevations in AST/ALT above 1.0 x ULN are not permitted
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times institutional upper limit of normal or =< 5 times institutional upper limit of normal in the presence of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 times institutional upper limit of normal or =< 5.0 times institutional upper limit of normal in the presence of liver metastases
+Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) ?3.0 × ULN (Upper limit of normal), unless considered due to leukemic organ involvement.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)\r\n* NOTE: this applies to patient in the normal and renal dysfunction cohorts (N, R3 and R4); patients with elevated AST and/or ALT may be assigned to liver dysfunction cohorts
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
+Alanine transaminase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times above the upper limits of the institutional normal (norm)
+Alanine aminotransferase and/or aspartate transaminase =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 times ULN*
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN if caused by liver metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (within 16 days before starting therapy)
+Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< grade 3
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 times normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x institutional upper limit of normal (ULN)
+Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) (must be within 7 days of MLA)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 6 x upper limits of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Aspartate aminotransferase (AST) =< 5 x institutional upper limits of normal (ULN)
+Acceptable hematology and serum biochemistry screening values: White Blood Cell Count (WBC) >= 1500/mm3; Absolute Neutrophil Count (ANC) >= 1,000/mm3; Platelet (PLT) count >= 75,000/mm3; Hemoglobin (HGB) >= 8 g/dl; Total bilirubin level <= 1.5 x institutional upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN; Creatinine <= 1.5 x ULN; Albumin > 25 g/L
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) below the institutional upper limits of normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 5 x upper limit of normal
+No liver metastases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; liver metastases: AST and ALT =< 5 x ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, or =< 5 x institutional ULN in subjects with liver metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) unless presence of hepatic metastasis in which case AST and ALT =< 5 x ULN are acceptable
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X upper limit of normal (ULN)
+AST and ALT < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal OR two downtrending values
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 1.5 x normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal if liver metastases present; otherwise, then =< 2.5 x upper limit
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 6 x upper limits of normal
+Hepatic: Serum total bilirubin ?1.5 x upper limit of normal (ULN) with the exception of <2.9 mg/dL for patients with Gilbert's disease, alanine aminotransferase (ALT/SGPT) and aspartate aminotransferase (AST/SGOT) ?2.5 x ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the institutional upper limit of normal
+Aspartate aminotransferase (AST) =< 1.5 times the upper limit of the normal range (x ULN)
+Alanine aminotransferase (ALT) =< 1.5 x ULN
+Aspartate aminotransferase (AST) + alanine aminotransferase (ALT) > 2 upper limits of normal value
+Obtained =< 7 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x institutional ULN
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Patient has poor liver function (> 2.5 times normal of alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) suggestive of cirrhosis or steatohepatitis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase must be within the range allowing for eligibility
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT) < 5 x ULN age
+Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note: If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor to discuss.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN (for patients with known liver metastasis, AST or ALT =< 3 x ULN is allowed) at the screening visit
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Have normal serum transaminase values (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
+Alanine transaminase (ALT) and aspartate aminotransferase (AST) ? 2.5 × ULN.
+Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN (or < 5 x ULN if known liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN (AST and ALT > 5 x ULN for subjects with liver metastasis)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN in the absence of liver metastases; AST and ALT =< 5 x ULN in the presence of liver metastases
+Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
+< 3 x upper limit of normal (ULN) alanine aminotransferase (ALT) and
+Patients must have the following screening results for hepatic function according to MD Anderson testing standards: total bilirubin < 1.5 times the upper limit of normal; alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST - if available) must be < 2 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
+Alanine aminotransferase (ALT) and aspartate transaminase (AST) less than or equal to 3 times the upper limit of the institution-established normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); in patients with liver dysfunction due to hepatic metastases, AST and ALT are permitted to be =< 5 times the ULN
+Hepatic: < 5 x upper limit of normal (ULN) alanine aminotransferase (ALT)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
+Within one week of study entry: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal, OR two consecutive downtrending values for patients who have undergone biliary stenting
+Aspartate aminotransferase (AST) =< 5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for the institution
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN if no liver involvement, or =< 5 X ULN with liver involvement
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN.
+Aspartate aminotransferase (AST) =< 3 X ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
+Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.0 x upper limits of normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal OR 5 x upper limit of normal (ULN) for patients status post (s/p) biliary stenting AND decreasing for at least two time points after stenting
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for institution or =< 5 x ULN for institution if clearly attributable to liver metastases
+AST and ALT no greater than 1.5 times ULN
+Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal range
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in AST/ALT above 1.0 X ULN are not permitted
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ~ 2.5 x ULN for subjects without liver metastasis ~ 5 times for liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
+Alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST) < 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x the upper limit of normal
+Aspartate aminotransferase (AST) =< 3 x upper limit of institutional normal
+Aspartate aminotransferase (AST) =< 1.5 x ULN
+Alanine aminotransferase (ALT) =< 1.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Alanine aminotransferase (ALT) > 2 x upper limit of normal
+Aspartate aminotransferase (AST) =< 3 x ULN
+Adequate liver function as evidenced by bilirubin less than 1.5 times the upper limits of normal (ULN) and alkaline phosphatase (AP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than 3 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT =< 5.0 x ULN
+For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine transaminase (ALT) < 2 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
+Aspartate aminotransferase (AST) =< 2 x the upper limits of normal
+Aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 2.5 times ULN
+Alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  =< 2.5 x ULN or =< 5.0 x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x upper limit of normal
+Aspartate aminotransferase (AST) =< 2.5 x the ULN for age (in the absence of hepatic involvement of tumor)
+ALT<2x ULN
+Hepatic: < 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (or =< 3 x ULN if liver involved with disease
+Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN
+Aspartate aminotransferase or alanine aminotransferase > 1.5 × ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Within 8 weeks of randomization: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) ?2.5 x ULN; ALT ?2.5 x ULN or AST/ALT <5 x ULN if liver involvement
+Alanine aminotransferase and aspartate aminotransferase < 2.5 of the ULN (< 5 x of ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
+Serum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) >= 3.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
+AST and ALT ? 2 x ULN
+Adequate hepatic and renal function laboratory values within 14 days prior to registration: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 X ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+AST/ALT < 3.0 x ULN
+AST/ALT < 3.0 x ULN
+Alanine aminotransferase (ALT) < 2 x the upper limit of normal
+Alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases present
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) >= 2.5 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2 × institutional upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 X upper limit of normal (ULN) (part 1 & 2)
+ALT or AST > 3.5 x ULN at screening
+Aspartate aminotransferase (AST) =< 2.5 x normal limits
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 5 times the upper limit of normal
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registration
+Alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registration
+Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
+Liver transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) less than 10 times the upper limit of normal (unless due to active myositis)
+Aspartate aminotransferase (AST) =< 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the upper limit of laboratory normal
+AST and ALT must be ? 5 x Upper Limit of Normal (ULN) if this elevation is solely due to ASM/MCL, otherwise AST, ALT must be ? 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 ULN in the presence of liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3.0 x the institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 times the upper limit of normal
+Alanine aminotransferase > 100 IU/L
+Aspartate aminotransferase > 100 IU/L
+Aspartate aminotransferase (AST) =< 2 times upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST) ?3 × ULN
+Alanine aminotransferase (ALT) ?3 × ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 Upper Limit of the Normal range (ULN) (or ? 5 if hepatic metastases are present)
+Aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper limit of normal (ULN); or ? 5.0 × ULN if liver metastases are present.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate and alanine aminotransferase (AST and ALT) =< 5 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal without evidence of active infectious hepatitis
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) for age
+Aspartate aminotransferase and/or alanine transaminase >5 times upper limit of normal.
+Alanine aminotransferase (ALT) < 3 x upper limit or normal (ULN)
+Serum AST and ALT ? 3 x ULN;
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase =< 3 X the upper normal limit of institution's normal range
+Aspartate aminotransferase and alanine aminotransferase values 3.0 x ULN (or 5x ULN in the case of patients with MF accompanied by hepatic extramedullary hematopoiesis, as manifested by any degree of hepatomegaly).
+Aspartate aminotransferase (AST) less 5x normal and alanine aminotransferase (ALT) 5x normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X normal institutional limits
+Alanine aminotransferase (ALT) =< 2.5 times ULN
+AST (Aspartate aminotransferase (GOT) and ALT (Alanine aminotransferase (GPT)) < 3.0 × ULN (upper limit of normal) or ? 5 × ULN if subject has documented liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless liver metastases, who can have AST/ALT =< 5 x ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless considered to be the result of leukemic involvement by the principal investigator (PI)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); ALT and AST up to 5 x ULN if liver metastases present
+Aspartate aminotransferase (AST) < 3 x upper normal limit (UNL)
+Alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ?3 × ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 times ULN for participants without liver metastases, or ?5 times ULN in the presence of liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of =< 2.5 x the upper limit of normal (ULN) or =< 5 x ULN if hepatic disease involvement is present as determined by the investigator
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times ULN for subjects without liver metastases, or ? 5 times ULN in the presence of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 times upper limit of normal (ULN) at screening.
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN (patients with documented liver metastases: AST and/or ALT =< 5 x ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5.0 times the upper limit of normal unless hepatic dysfunction is related to liver involvement with disease
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x ULN in pts without liver metastasis; for pts with liver metastasis: ALT or AST > 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with hepatic involvement with tumor)
+Hepatic function: Total bilirubin < 1.5 × upper limit of normal (ULN) (except in the case of subjects with known Gilbert's disease: < 5 × ULN) and transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) < 3 × ULN based on age- and institution specific laboratory-specific normal ranges
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or =< 3.0 x upper limit of normal [ULN] if liver metastases are present)
+Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 times the upper limit of normal (ULN)
+AST and/or ALT >= 3 times the ULN
+Aspartate aminotransferase or alanine aminotransferase > 3 times the upper limit of normal.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x ULN for subjects without liver metastasis; =< 5 times for liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered due to leukemic involvement)
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Serum total Bilirubin ? 1.5 x ULN (upper limit of normal) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 2.5 x ULN
+Aspartate aminotransferase (AST) =< 1.5 x upper limit of normal
+Alanine aminotransferase (ALT) =< 1.5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x the upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ?3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 2.5 times the upper limit of normal; in patients with liver metastasis, liver function tests should be < 5 times the upper limit of normal
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >= 3 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
+Alanine aminotransferase and aspartate aminotransferase </= 3 times the ULN
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal
+Alanine aminotransferase (ALT) < 300 IU/ml
+Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > 3.0 x ULN (or < 5.0 x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper normal limit (=< 5 x upper normal limit if documented hepatic involvement with lymphoma)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ? 5 x ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) within 14 days prior to registration
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Serum AST or ALT ? 1.2 x ULN
+Patients must have adequate hepatic function with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN within one week prior to treatment
+Elevated serum aspartate aminotransferase, alanine aminotransferase, or bilirubin (unless there is medical justification for bilirubin elevation, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase are normal)
+Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN for patients with documented liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN, or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancy
+Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? 2.5 x ULN in the absence of liver metastases or =< 5 ULN in case of liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) =< 3 x ULN for the institution (=< 5 x ULN is acceptable if liver has tumor involvement)
+Alanine aminotransferase (ALT) > 2.5 times upper normal limit (unless due to disease involvement of liver)
+Aspartate aminotransferase ?3 × ULN for the reference lab (?5 × ULN for subjects with known hepatic metastases)
+Alanine aminotransferase ?3 × ULN for the reference lab (?5 × ULN for subjects with known hepatic metastases)
+Bilirubin =< 1.5 mg/dL AND alkaline phosphatase =< 3 x the upper limit of normal (ULN) for the reference lab (=< 5x the ULN for patients with known hepatic metastases and no limit for patients with known bone metastases) AND aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3x the ULN ( =< 5x the ULN for patients with known hepatic metastases)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) < 5 x upper limit of normal
+Aspartate aminotransferase (AST) < 5 x upper limit of normal
+Serum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) < 2.5 x ULN; for patients with liver metastases, ALT/AST < 5 x ULN is acceptable
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (for subjects with liver metastases AST/ALT may be =< 5 x ULN)
+Aspartate aminotransferase (AST) and alkaline phosphatase =< 2.5 x ULN (CTCAE v4.03 grade 1; AST and alanine aminotransferase [ALT] =< 3 x ULN [or =< 5.0 x ULN if hepatic metastases are present])
+Bilirubin <2 x upper limit of normal (ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) <3 x ULN
+Within 14 days prior to first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN) (unless the patient has Gilbert’s syndrome, in which case AST and ALT =< 5.0 x ULN is permitted
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal range (ULN)
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 times the upper limits of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x ULN, +/- 7 days from date of ICF signing
+Serum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) =< 5 x ULN
+Serum ALT/AST <2.5 ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) must be =< 1.5 x ULN for the lab
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN unless metastatic to liver in which case AST and ALT should be < 5 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, unless due to liver involvement with lymphoma
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit of normal
+Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) levels must be =< 2.5 x ULN, or =< 5 X ULN for patients with liver involvement by lymphoma
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x institutional upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
+Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x upper limit of normal (ULN) or AST or ALT ? 5 x ULN if liver is involved by disease process as judged by the investigator
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 2.5X the ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless ALT or AST elevation is thought to be related to underlying AML, in which case ALT and AST should be =< 5.0 x ULN
+Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN), or AST or ALT greater than 5 times the ULN for those with Gilbert syndrome.
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x UNL
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2 × upper limit of normal (ULN),
+Aspartate aminotransferase (AST) =< 5 x the upper limit of normal; alanine aminotransferase (ALT) =< 5 x the upper limit of normal
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 upper limit of normal (ULN); if liver function abnormalities are due to the underlying malignancy, then AST and ALT must be ? 5 ULN;
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5.0 × ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of the institution-established normal range
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN for age
+alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 times the ULN for the reference lab
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented liver metastases, the AST/ALT may be =< 5 x ULN
+Adequate laboratory parameters [absolute neutrophil (ANC), platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine and coagulation parameters] at screening
+Alanine aminotransferase (ALT) less than 3 X upper limit of normal, aspartate aminotransferase (AST) less than 3 X upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 5 x upper limit of normal, and
+ALT and AST ? 2.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
+Participants with normal major organ functions as defined by hemoglobin (HgB) >= 8.5 gram/decilitre (dL), absolute neutrophil count (ANC) >= 1000/microliter (mcL), platelet >= 60,000/micL, aspartate aminotransferase/alanine transaminase (AST/ALT) <= 3 x Upper Limit of Normal (ULN), total Bilirubin <= 2 x ULN, creatinine <= 2 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), with the following exceptions: patients with documented liver metastases: AST and/or ALT =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 ×ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN (or < 5 x ULN in subjects with liver metastases or hepatocellular carcinoma).
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2x institutional ULN unless it is related to the primary disease
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of =< 2 ULN
+Subject has total serum bilirubin ?1.5 times the upper limit of normal (ULN),serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 times ULN, or albumin ? 3.0 g/dL at Screening.
+Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >1.5 x Upper limit of normal (ULN).
+The subject has aspartate aminotransferase and/or alanine aminotransferase > 1.5 × ULN, with concomitant alkaline phosphatase > 2.5 × ULN.
+Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
+Aspartate aminotransferase (AST) < 2 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </=2.5 times ULN (</=5 times ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 2.5 times the upper limit of normal
+Patients are eligible with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measuring up to 5 x upper limit of normal (ULN) given the presence of liver metastasis
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times institutional upper normal level (AST and ALT =< 5 times institutional upper normal level, if there is evidence of liver metastasis)
+Alanine aminotransferase (ALT) =< 3 x ULN and aspartate aminotransferase (AST) =< 3 x ULN
+AST and ALT ? 2.5 X ULN
+Alanine aminotransferase (ALT) =< 5 times the upper limit of normal for age
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
+Alanine aminotransferase (ALT) =< 5 x the upper limit of normal for age
+Aspartate aminotransferase (AST) =< 5 x the upper limit of normal for age
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x the upper limits of normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
+- Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT) = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT are eligible
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
+Adequate hepatic function: serum total bilirubin ? 2X greater than the upper limit of normal (ULN) (? 3X ULN in subjects with liver metastases), aspartate aminotransferase) AST) / alanine aminotransferase (AST) ? 2X the ULN for the local reference lab (? 5X the ULN for subjects with liver metastases)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) <=2.5*ULN • For participants to be treated with MLN4924 + docetaxel in Part B, AST and ALT must be <=1.5*ULN, and total bilirubin should be within the normal range.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN; if liver metastases are present, =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 × upper limit of normal (ULN); patient with liver metastases =< 5 ×ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 5 × institutional upper limit of normal (ULN) for cases involving liver metastasis and ? 2.5 ×ULN for all other cases
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x institutional upper limit normal (ULN)
+Alanine aminotransferase and AST ? 2.5 × ULN; for subjects with hepatic metastases, ALT and AST ? 5 × ULN
+Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN or =< 5.0 x ULN in case of documented hepatic metastasis
+Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) or 3 x IULN with normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with Gilbert’s disease
+Adequate hepatic parameters as defined by total bilirubin ? 1.5 x upper limit of normal (ULN) and aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5xULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver involvement of their cancer)
+Alanine aminotransferase (ALT)? 3 x upper limit of normal (ULN) or ? 5x ULN if liver metastasis is present
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (ALT and AST =< 2.5 x ULN is acceptable if there is liver metastasis)
+Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Hepatic: Direct bilirubin ?1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ? 5.0 X ULN is allowed
+Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 × the upper limit normal (ULN) for the institution (>= 5 × if due to hepatic involvement by tumor)
+Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
+Total bilirubin level ?1.5 times institutional upper limit of normal (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?2.0 x ULN except in subjects with known hepatic metastasis, where AST or ALT can be ?5.0 x ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 ULN if hepatic involvement is present as determined by the investigator
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN obtained =< 7 days prior to registration (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 3 x ULN
+Alanine aminotransferase (ALT) <2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) <2.5 x UNL
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
+Alanine aminotransferase (ALT) =< 1.5 X ULN
+Aspartate aminotransferase (AST) =< 1.5 X ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4.0 x upper limit of normal; this requirement reflects the excretion of CPX-351 by the liver
+Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ?2.5 X ULN (?5 x ULN in patients with liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entry
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (with or without liver metastases)
+Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
+Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.5 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Total bilirubin (TBL), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal
+Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) < 5.0x the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN or < 5 x ULN if known liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+< 3 x ULN alanine aminotransferase (ALT), unless there is congenital benign hyperbilirubinemia
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 14 days prior to initiation of study drug
+Cohort A: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x ULN
+Aspartate aminotransferase (AST) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)
+Alanine aminotransferase (ALT) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); except for patients with hepatic metastases: ALT and AST =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within =< 3 x upper limit of normal
+Aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN) and alanine aminotransferase (ALT) =< 5 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3 x the upper limit of normal (ULN); however, ALT, AST, and TBILI each ? 5 x ULN is acceptable if the elevation is considered by the investigator to be due to PTLD involvement of the liver
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5 × ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5× ULN
+Alanine aminotransferase (ALT) =< 3 times the upper limit of normal for age
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 x ULN unless liver metastasis is present then up to 5 X ULN permitted
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
+Alanine aminotransferase (ALT) ?3xULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than three times the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 X ULN in case of liver metastases
+AST & ALT ? 2.5 x ULN
+Adequate hepatic function within 21 days prior to randomization, with bilirubin < 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN.
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN;
+Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit normal (ULN)
+Alanine aminotransferase (ALT) < 2.5 X institutional upper limit of normal
+Aspartate aminotransferase (AST) < 2.5 X institutional upper limit of normal
+Elevated liver function tests (LFTs): Serum bilirubin >upper limit of normal (ULN), alanine (ALT) or aspartate (AST) aminotransferase > 1.5 ULN concomitant with alkaline phosphatase > 2.5 ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
+Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN. For total ALP greater than 3 times ULN, the ALP liver isoenzyme must be less than or equal to 3 times ULN.
+Alanine aminotransferase (ALT) =< 5 x ULN for age, unless the elevation is disease-related
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 10 × upper limit of normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALK PHOS) must be within the range allowing for eligibility:\r\n* ALK PHOS =< ULN AND AST or ALT =< 1.5 X ULN\r\n* ALK PHOS > 1 X ULN but =< 2.5 ULN AND AST or ALT =< 1.5 X ULN\r\n* ALK PHOS > 2.5 X ULN but =< 5 X ULN AND AST or ALT =< ULN
+Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times the ULN (>= 5 x ULN for patients with liver involvement)
+Patients enrolled with hepatic dysfunction must have laboratory test results for total bilirubin of >1.5x to <=3x the upper limit of normal (ULN) and liver function tests (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) of <8x the ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limits of normal
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP): all three < 2.5 x ULRR, or < 5 x ULRR if judged by the investigator to be related to liver metastases
+ALT and/or AST ?2.5 X ULN
+ALT and/or AST ?2.5X ULN
+ALT and/or AST ?3X ULN
+ALT and/or AST ?3X ULN
+ALT or AST > 3 x ULN
+Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5x the upper limit of normal, except in the presence of known liver metastases in which case levels may be up to 5x the upper limit of normal (ULN)
+Had at least one liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) with normal results in the last year
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal if no liver involvement or =< 5 times the upper limit of normal with liver involvement
+Serum total bilirubin less than 2.5 mg/dl, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of normal; ALT and AST values above these levels may be accepted (up to a maximum of 5 times the upper limit of normal), at the discretion of the principal investigator (PI) or study chairperson, if such elevations are thought to be due to liver involvement by malignancy
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN)
+AST and ALT =< 2.5 x ULN
+AST and ALT < 2.5 x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
+Alanine aminotransferase (ALT) and aspartate transaminase (AST) ?2.5*upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits
+Normal organ function tests including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) < 3 × upper limit of normal.
+Serum alanine aminotransferase < 2.5 times the ULN.
+AST or ALT < 1.5 times ULN for age
+Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 5 times ULN
+Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note:If elevated liver enzymes are related to disease; contact medical monitor to discuss.
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional upper limit of normal (ULN) and total bilirubin < 1.5 x institutional ULN
+Aspartate aminotransferase (AST) =< 3 times ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)
+Alanine aminotransferase and/or aspartate transaminase < 3.0 x ULN (or < 5.0 x ULN if deemed to be elevated due to leukemia)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 the upper limit of normal (ULN); < 5 ULN if there is liver involvement secondary to the tumor
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and ALT < 3.0 × ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) (=< 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< to 2.5 times the upper limit of normal
+Aspartate aminotransferase (AST) =< 3 times ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); patient with liver metastases =< 5 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 upper limit normal (ULN), or < 3 x ULN if liver metastases are present
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 2.5 the upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3.0 x upper limits of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 x the upper limit of normal (ULN) for the laboratory (lab) being used
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
+Aspartate aminotransferase (AST) < 2 x upper limit of normal (ULN)
+Alanine aminotransferase or aspartate aminotransferase >= 2.5 x ULN
+Alanine aminotransferase (ALT) 5 x upper limit of normal (based on institutional standards)
+Aspartate aminotransferase (AST) 5 x upper limit of normal (based on institutional standards)
+Hepatic: total bilirubin less than or equal to (<=) 1.5 times the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5*ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x ULN (5 x ULN for those with lymphoma involvement of the liver)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 2.5 x IULN within 28 days prior to registration
+Aspartame aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Hepatic: total bilirubin less than or equal to (<=) 1.5*the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and AST <=2.5*ULN.
+Aspartate aminotransferase (AST) =< 2.5 x ULN
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Liver function tests (LFTs) (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 3 X upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) with the following exception: patients with documented liver metastases should have AST and ALT =< 5 x ULN (obtained within 28 days prior to the first study treatment)
+Moderate to severe liver failure (defined as alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times upper limit of normal if no liver metastases are present; ALT or AST > 5 times upper limit of normal if liver metastases are present)
+Patients with history of severe liver disease, defined as and confirmed by elevated alanine aminotransferase\r\n(ALT) and aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal.
+Aspartate aminotransferase (AST, and alanine aminotransferase (ALT) =< 1.5 x ULN.
+AST, and ALT > 1.5 x ULN
+Laboratory tests (transaminases [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)], blood urea nitrogen [BUN] and creatinine not greater than twice normal) and normal electrocardiogram (ECG)
+Is known or suspected to have significant hepatic dysfunction, with aspartate aminotransferase (AST) & alanine aminotransferase (ALT) 3 times above upper limit of normal (ULN) per institutional laboratory
+Obtained =< 30 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal
+Patients with severe hepatic impairment as defined as aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than three times the upper limit of normal and/or, total bilirubin greater than 3 mg/dL, and/or Child-Pugh score > 9
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than 5 times the upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x institutional upper limit of normal (IULN)
+Aspartate aminotransferase (AST) =< 1.5 x upper limits of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasis
+Serum aspartate aminotransferase (AST) =< 1.5 times the upper limit of normal
+Aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN) for the laboratory
+Alanine aminotransferase (ALT) > 3 x ULN for the laboratory
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3 x ULN
+Obtained within 14 days prior to initiation of treatment: Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULN
+Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= 2.5 times the upper limits of normal (ULN) 14 days prior to study enrollment
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 upper limit of normal (ULN)
+Hepatic: < 3 x upper limit of normal (ULN) alanine aminotransferase (ALT)
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x the upper normal limit
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 10 times institutional upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5.0 x upper limit of normal as evidenced by impairment of baseline laboratory values
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN)
+Significant hepatic (serum aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] > 3 time upper limit of normal institutional normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for institution
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both within 3 x upper limit of normal based on institutional values
+Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 20 x upper limit of normal (ULN) or
+Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Aspartate aminotransferase (AST) < 5 x ULN
+Obtained =< 30 days prior to randomization: Alanine aminotransferase (ALT) or aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal
+Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ? 2.5xULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5.0 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, obtained within 14 days of the first dose of study drug
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN) if no hepatic metastases are present; >5 × ULN if hepatic metastases are present
+Screening chemistry values of the following: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ? 3.0 × upper limit of the normal (ULN), total bilirubin ? 1.5 × ULN, Creatinine ? 1.5 × ULN;
+Alanine transaminase (alanine aminotransferase [ALT]) =< 2 x upper normal limit (ULN) (in the expansion cohort, patients with known liver involvement may have ALT =< 5 x ULN); aspartate aminotransferase (AST) =< 2 x ULN (in the expansion cohort, patients with known liver involvement may have AST =< 5 x ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the upper limit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal
+The screening results for alanine aminotransferase (ALT) must be < 2 times the upper limit of normal
+The screening results for aspartate aminotransferase (AST), if available, must be < 2 times the upper limit of normal
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X upper limit of normal (ULN) (or =< 5 X ULN if hepatic metastases are present)
+Alanine aminotransferase (ALT) greater than 2 x upper limit of normal (> 75 U/L)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be < 3.0 times the upper limit of the institutional normal range; test results must be no more than 3 months old
+Alanine aminotransferase (ALT) must be < 2 times the upper limit of normal; if available, screening results for aspartate aminotransferase (AST) must be < 2 times the upper limit of normal
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) lower than three times the upper\r\nlimit of normal
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/L
+Minocycline trial only: screening results for aspartate aminotransferase (AST) must be < 3 times the upper limit of normal
+Patient with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) three times the upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
+Serum aspartate aminotransferase (AST) ? 2.0 x upper limit of normal (ULN)
+Serum alanine aminotransferase ? (ALT) 2.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x institutional ULN
+An aspartate aminotransferase (AST) less than 2 times the upper limit of normal, unless these values are due to underlying hematologic malignancy
+Alanine aminotransferase (ALT) equal to or less than two times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 times the upper normal limit
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be < 2 times the upper limit of normal, as evidenced in laboratory values =< 3 months old
+Known alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR or
+Total bilirubin =< 1.5 x upper limit of normal (ULN) except for Gilbert syndrome or cases clearly not indicative of inadequate organ function, i.e., elevation of indirect (hemolytic) bilirubin in the absence of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) abnormality
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times upper limits of normal prior to chemotherapy
+Aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN), unless hepatic dysfunction is a manifestation of cGVHD
+Aspartate aminotransferase (AST) =< 3 x upper limit normal
+DONOR: Active liver disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels > 2 times the upper limit of normal [ULN])
+Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN)
+Aspartate aminotransferase (AST) < 5.0 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x upper limit of normal
+Alanine aminotransferase (ALT) < 1.5 x ULN, aspartate aminotransferase (AST) < 1.5 x ULN
+Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times upper limit of institutional normal
+Liver dysfunction manifested by SGTP (ALT) > 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) >5 X ULN and/or direct (conjugated) bilirubin > 2X ULN
+Alanine aminotransferase (ALT) or aspartate transaminase (AST) =< 3 x upper limit of normal (ULN) obtained =< 30 days prior to registration
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless benign congenital hyperbilirubinemia)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN
+Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal range (ULN); for subjects with known liver metastases =< 5 x ULN, and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with known liver metastases =< 5 x ULN
+Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 2 times upper limit of normal values
+Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (unless determined by treating physician to be related to underlying malignancy)
+Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3.0 x upper limit of normal (ULN)
+Have significant hepatic dysfunction (aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 2 x ULN or reported liver disease)
+Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 1.5 x upper limit of normal (ULN)
+Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) < 3 times upper limit of normal values
+DONOR: History of liver disease; a donor with a history of liver disease would be eligible if the serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are < 2 times upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (CTCAE grade 2)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 1.5 x upper limit of institutional normal
+Alanine aminotransferase (ALT) =< 1.5 x upper limit of institutional normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
+Alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST) =< 2 x institutional ULN
+Alanine aminotransferase level (ALT) =< 3 x the upper limit of normal (ULN), within 30 days prior to enrollment
+Aspartate aminotransferase level (AST) =< 3 x ULN, within 30 days prior to enrollment
+Has laboratory results that are outside of normal limits at screening, as follows: a) Moderate or severe liver dysfunction, as defined as: Aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN), OR Alanine aminotransferase (ALT) > 5 times the ULN, OR Serum total bilirubin >2.5 times the ULN, OR AST or ALT > 3 times ULN with total bilirubin > 2 times ULN; b) Calculated creatinine clearance <30 mL/min.
+Aspartate Aminotransferase (AST) and Alanine transaminase (ALT) <10x upper limit of normal
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 5 x upper limit of normal (ULN) (unless due to liver metastasis)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
+Aspartate aminotransferase (AST) =< 5 x normal
+Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (subjects with documented liver metastases should have AST =< 5 x ULN)
+Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (subjects with documented liver metastases should have ALT =< 5 x ULN)
+Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
+Aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x ULN
+Aspartate aminotransferase (AST) =< 1.8 X upper limit of normal (ULN)
+Alanine aminotransferase (ALT) =< 1.8 X ULN
+Alanine aminotransferase (ALT) >= 2.0 x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR
+Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x the upper normal limit
+Aspartate aminotransferase (AST) =< upper limit of institutional normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) within 2 x ULN
+Alanine aminotransferase (ALT) < 5 X institutional upper limit of normal (ULN)
+Aspartate aminotransferase (AST) < 5 X institutional ULN
+Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 3 x of the upper limits of normal
+Individuals with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x normal upper limit any time during the previous 2 months
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN, obtained within 14 days prior to PET scan
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary disease
+Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
+Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN obtained < 2 weeks prior to study enrollment
+Elevated liver function tests (LFTs) (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP] or bilirubin levels greater than 2.5 times the normal limit) from laboratory tests conducted within 30 days prior to surgery
+Patients with liver dysfunction: total bilirubin > 2.5 mg/dl; albumin < 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 5 times upper limits of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN (institutional upper limits of normal); > 5 x ULN if liver metastasis
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Abnormal liver functions consisting of any of the following:\r\n* Serum bilirubin >= 1.5 x ULN (except for patients with documented Gilbert’s disease)\r\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN, (for patients with known liver metastasis, AST or ALT =< 5 x ULN is allowed)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) greater than 2.5 x upper limits of normal
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine and aspartate aminotransferase (ALT/AST) =< 2.5 x upper limit of normal (ULN) obtained =< 14 days prior to registration
+Aspartate aminotransferase (AST) and ALT ?2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
+Liver function: total bilirubin ? 1.5 times the upper limit of normal (ULN) of each institution, aspartate aminotransferase and alanine aminotransferase ? 3 times the ULN range of each institution.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN)
+AST/ALT < 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, completed within 2 weeks prior to start of protocol therapy
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN in the absence of known metastatic involvement of the liver or AST and ALT =< 5.0 x ULN if there is metastatic liver involvement
+Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
+Aspartate aminotransferase (AST) =< 1.5 x ULN
+Alanine aminotransferase (ALT) =< 1.5 x ULN
+Patients with depressed liver function, as assessed with a screening liver function test (LFT) yielding serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the institutional upper limit of normal; or total bilirubin greater than 2 mg/dL
+ALT > 1.5 x ULN
+Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal
+Alanine aminotransferase (ALT) =< 2.5 x ULN
+Alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within normal institutional limits
+Aspartate aminotransferase (AST) > 3 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal, unless attributed to tumor, obtained within 2 weeks prior to registration
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN
+c. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3.0 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, AST and ALT must be =< 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5×ULN.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
+Have normal serum transaminase values (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN for the lab utilized
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjects
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) within the normal range at the screening visit
+Aspartate aminotransferase =< 45 IU/dL
+Alanine aminotransferase =< 40 IU/dL
+Greater than 3 x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal unless the liver is involved with tumor, in that case, ALT/AST must be =< 5 x upper limit of normal
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits
+Have adequate organ function, including: Hepatic: Bilirubin ?1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3.0 × ULN. For participants with tumor involvement of the liver, AST and ALT ?5.0 × ULN are acceptable. For participants with tumor involvement of the bone, alkaline phosphatase ?5.0 × ULN is acceptable. Renal: Serum creatinine ?2.0 × ULN. Absolute neutrophil count (ANC) ?1.0 × 109/liter (L). Hemoglobin ?9 grams per deciliter (5.58 millimoles per liter). Platelets ?90 × 109/L.
+Hepatic: bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) ?3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X institutional upper limit of normal
+Laboratory values for hemoglobin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum creatinine or calculated/measured creatinine clearance.
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
+Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin.
+Hepatic: total bilirubin less than or equal to (<=) 1.5*the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5*ULN.
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at screening > 3x upper limit of normal (ULN)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be <=2.5*ULN.
+AST ? 3.0 x ULN
+ALT ? 3.0 x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x ULN if no liver involvement or ?5 x ULN with liver involvement.
+Total bilirubin ?1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5*ULN (?5*ULN if liver metastases are present).
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN (? 5 times ULN for patients with impaired liver function due primary tumor or metastatic disease)
+Aspartate aminotransferase or alanine aminotransferase at screening >3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement
+Serum/plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.
+aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 X institutional UNL,
+Alanine aminotransferase (ALT) =< 1.5 times upper limit of normal